



Published in final edited form as:

J Org Chem. 2018 December 21; 83(24): 15347–15360. doi:10.1021/acs.joc.8b02606.

Three-Component Coupling of Aldehydes, Aminopyrazoles and Sulfoxonium Ylides via Rhodium(III)-Catalyzed Imidoyl C–H Activation: Synthesis of Pyrazolo[1,5-*a*]pyrimidines


Gia L. Hoang, Andrew D. Streit, and Jonathan A. Ellman*

Department of Chemistry, Yale University, 225 Prospect St., New Haven, CT 06520 (USA)

Abstract

An efficient, three-component strategy for Rh(III)-catalyzed annulation of readily available 3-aminopyrazoles, aldehydes, and sulfoxonium ylides to give diverse pyrazolo[1,5-*a*]pyrimidines is disclosed. The reactions were performed under straightforward benchtop conditions using microwave heating with short reaction times. Good yields were obtained for a number of substituted aminopyrazoles and a very large variety of aromatic and heteroaromatic aldehydes, including those incorporating electron-withdrawing, electron-donating, basic nitrogen, halide and acidic functionality. Ester and methoxy functionalities could also be directly installed on the pyrimidine ring by employing ethyl glyoxylate and trimethyl orthoformate in place of the aldehyde, respectively. Additionally, a range of sulfoxonium ylides provided products in good yields to establish that aryl, heteroaryl, and branched and unbranched alkyl substituents can be introduced with this reagent. Finally, the first use of a formyl sulfoxonium ylide in a chemical transformation enabled the preparation of products with only a single substituent on the pyrimidine ring as introduced by the aldehyde coupling partner. For the formyl ylide, a one-pot, stepwise reaction sequence was used to prevent competitive condensation of the formyl group with the aminopyrazole.

Graphical Abstract



*Corresponding Author: jonathan.ellman@yale.edu.

Supporting Information. This material is available free of charge via the Internet at <http://pubs.acs.org>.
NMR spectra (PDF)

Notes

The authors declare no competing financial interest

INTRODUCTION

Fused [5,6]-bicyclic bridgehead nitrogen heterocycles are privileged pharmacophores in drug discovery. The azolopyrimidines are the most prevalent subclass, and are featured in many U.S. FDA approved drugs and even more clinical candidates.^{1,2} We have recently reported the first examples of imidoyl C–H activation via Rh(III)-catalyzed two-component annulations of *N*-azolo imines **1** with alkynes, diazoketones and sulfoxonium ylides to give azolopyrimidines **2** (Scheme 1A).^{3,4} Moreover, annulations with 1,4,2-dioxazol-5-one amidating reagents afforded a wide range of azolo[1,3,5]triazines **3**.^{5,6} A particularly attractive feature of the aforementioned approach is the large number of diverse *N*-azolo imines **1** that can readily be prepared from commercially available aminoazoles and aldehydes.

Multi-component reactions enable access to complex structures from simple precursors. In work relevant to *N*-fused [5,6]-bicyclic heterocycle synthesis, the Groebke–Blackburn–Bienaymé (GBBR) reaction is a popular and efficient approach (Scheme 1B).⁷ In this three-component reaction, imines formed *in situ* couple with isocyanides to afford a wide range of fused imidazole bridgehead nitrogen heterocycles **4**.

Herein, we report the multi-component synthesis of pyrazolopyrimidines **8** (Scheme 1C), which are found in more approved drugs and clinical candidates than any other subclass of [5,6]-bicyclic bridgehead nitrogen heterocycles.¹ In this three-component coupling reaction, imines that are formed *in situ* from readily available aldehydes **5** and aminoazoles **6**, undergo Rh-catalyzed annulation with sulfoxonium ylides **7**, which are stable, crystalline carbene equivalents that are increasingly used in Rh(III)-catalyzed C–H functionalization.^{8,9} The rapid preparation of diverse pyrazolopyrimidines **8** is further facilitated by the use of a commercially available and air stable Rh(III) catalyst, convenient benchtop set up, and short reaction times with microwave heating.

High functional group compatibility is an important aspect of this three-component reaction, with unhindered basic heterocycle nitrogens, amides, esters, secondary and tertiary carbamates, halides, carboxylic acids and acidic secondary anilides all successfully incorporated. Ester and methoxy functionalities can be directly installed on the pyrimidine ring by employing ethyl glyoxylate and trimethyl orthoformate in place of the aldehyde, respectively.

We also report the efficient preparation of pyrazolopyrimidines **8** with only a single substituent on the pyrimidine ring (bottom of Scheme 1C). In a one-pot reaction, stepwise formation of *N*-azolo imines is followed by addition of the formyl ylide **7i** and the Rh(III) catalyst. To our knowledge this is the first chemical transformation of a formyl sulfoxonium ylide.

RESULTS AND DISCUSSION

A large variety of reaction parameters were first examined for coupling benzaldehyde (**5a**), aminopyrazole **6a**, and sulfoxonium ylide **7a** to give pyrazolopyrimidine **8aaa** (Table 1). This investigation established that good yields of **8aaa** could be obtained by benchtop set up

using the commercially available and air stable cationic catalyst $[\text{Cp}^*\text{Rh}(\text{MeCN})_3](\text{SbF}_6)_2$ with KOAc, pivalic acid (PivOH) and 3\AA sieves as additives in dioxane (0.2 M) under microwave (MW) conditions at $150\text{ }^\circ\text{C}$ for 1 h (entry 1, Table 1). When the halide was not abstracted from $[\text{Cp}^*\text{RhCl}_2]_2$, a slight reduction in yield of the product was observed (entry 2). As expected, when a Rh(III) catalyst was not added, no product was obtained (entry 3). NaOAc was found to be less effective than KOAc (entry 4), and completely removing the base led to a further reduction in the yield (entry 5). Removing the PivOH also resulted in a significantly lower yield (entry 6). Increasing the temperature to $160\text{ }^\circ\text{C}$ did not improve the yield indicating that more forcing conditions are not necessary (entry 7). Chlorobenzene, a typical solvent for microwave reactions was tested and found to be less effective (entry 8). Reducing the amount of sulfoxonium ylide (1.1 equiv) led to only a slightly lower yield (entry 9). In comparison to $\text{Cp}^*\text{Rh}(\text{III})$ catalysis, $\text{Cp}^*\text{Ir}(\text{III})$ and $\text{Cp}^*\text{Co}(\text{III})$ catalysts were much less effective (entries 10 and 11).

Concentration is important as might be expected for a multicomponent reaction (entries 12 and 13), with a higher 0.4 M concentration resulting in an appreciable increase in yield (entry 13). We did not explore further increases in the concentration due to the amount of 3\AA sieves used (ca. 100 mg per 0.1 mmol of limiting reagent), although it should be noted that only a modest reduction in yield was observed when 3\AA sieve were not added (entry 14).

Consistent with our goal to provide access to diverse pyrazolopyrimidines **8** at short reaction times, we chose 10 mol % catalyst loading for evaluating substrate scope. However, 5 and 2.5 mol % catalyst loading did afford significant amounts of the desired product (entries 15 and 16). Lower catalyst loadings are therefore likely to be applicable to many starting material combinations (*vide infra*) as well as by employing more forcing reaction conditions. Finally, an 82% yield for this three-component reaction was observed by employing conventional heating for 16 h at $100\text{ }^\circ\text{C}$, a temperature lower than the boiling point of the dioxane solvent (entry 17).

Using the optimal reaction conditions (i.e., entry 13, Table 1), we first explored aldehyde scope for three-component coupling with aminopyrazole **6a** and sulfoxonium ylide **7a** (Scheme 2). Benzaldehydes with electron withdrawing and donating groups at the *para*-position gave pyrazolopyrimidines **8baa** and **8caa** in 78% and 80% yields, respectively, establishing that the reaction is effective regardless of the electron properties of the aldehyde input. Benzaldehydes substituted at the *meta*- and *ortho*-positions were also effective coupling partners as exemplified by the halo substituted products **8daa** and **8eaa**, respectively. However, a moderate reduction in yield was observed for *ortho* substituted product **8eaa**.

Benzaldehydes bearing a large variety of useful functional groups were effective inputs. For example, good yields were obtained for pyrazolopyrimidine products displaying ester (**8faa**), carboxylic acid (**8gaa**), and acidic secondary anilide (**8haa**) functionality.

Pyridinecarboxaldehydes were also effective inputs. Notably, unhindered basic heterocyclic nitrogens do not interfere with this directed C-H functionalization reaction as demonstrated by the incorporation of 4-pyridinecarboxaldehyde to give **8iaa** in 58% yield. The 4-acetamido and 4-chloro substituted 3-pyridinecarboxaldehydes also coupled effectively to

give **8jaa** and **8kaa** in 77 and 66% yields, respectively. The chloropyridine substituent in **8kaa** as well as the bromophenyl substituent in **8daa** provide versatile sites for incorporating additional functionality. These examples highlight the compatibility of haloarene functionality with the three-component reaction conditions. This outcome contrasts with methods to elaborate pyrazolopyrimidine frameworks by using cross-coupling to introduce aromatic substituents, which inherently rely on reactions that proceed by aryl halide oxidative addition.¹⁰

Five-membered furan-, thiophene- and pyrazolecarboxaldehydes provided **8laa–naa** in excellent yields (81–85%). Notably, the *N*-alkyl pyrazolyl motif in **8naa** is incorporated into a number of approved kinase inhibitor drugs and drug candidates with [5,6]-bicyclic nitrogen heterocycle pharmacophores such as the approved janus kinase inhibitor drugs ruxolitinib and baricitinib.¹¹ Lastly, enolizable aldehydes, provide the desired pyrazolopyrimidines **8** in poor yields as exemplified by **8oaa** obtained in 13% yield from acetaldehyde.

We next investigated the scope for the sulfoxonium ylides **7** (Scheme 3). Significantly, these ylides can readily be prepared by straightforward one-step protocols from trimethylsulfoxonium iodide and acid chlorides or activated esters.^{8,9} In addition to employing the *N*Boc-piperidine ylide **7a** input, another example of the incorporation of an α -branched substituent is provided by the isopropyl substituted pyrazolopyrimidine product **8aab**, which was obtained in 79% yield. Methyl, β -branched and *N*-Boc-ethyl substituted products **8aac–aae** were also obtained in excellent yields (80–94%). Electron-rich and -poor aryl-substituted ylides efficiently coupled to give **8aaf** (89%) and **8aag** (87%), respectively. These results when considered along with the successful incorporation of electron-poor and -rich benzaldehydes such as for **8baa** and **8caa** (Scheme 2), clearly establish that the regioselective introduction of aromatic substituents regardless of electronic properties can be achieved. In contrast, while the efficient preparation of pyrazolopyrimidines can be accomplished by condensations of 3-aminopyrazole with symmetrical 1,3-dicarbonyl compounds, this approach generally provides mixtures of regioisomers when unsymmetrical diketones are employed.¹² Finally, the effective incorporation of a heteroaryl-substituted ylide was demonstrated by the preparation of thiophenyl substituted **8aah** in 85% yield.

As depicted in Scheme 4, we next evaluated the scope for the aminopyrazoles, many of which are commercially available or straightforward to prepare in high yields.¹³ Using standard conditions for 4-phenyl-substituted 3-aminopyrazole (**6a**), 4-methyl-substituted 3-aminopyrazole efficiently provided pyrazolopyrimidine **8aba** in 71% yield. Disubstituted aminopyrazoles also coupled efficiently to give **8aca** and **8ada**. Unsubstituted and 5-*tert*-butyl-substituted aminopyrazoles were also effective inputs providing **8aea** in 62% and **8afa** in 73% yields, respectively. It should be noted that for these inputs, a modest improvement in the product yields were achieved by lowering the concentration to 0.2 M. Therefore, 0.2 M was chosen for the evaluation of other 5-substituted-3-aminopyrazoles, including those with methyl, isopropyl, cyclopropyl, and phenyl substituents, which gave **8aga–8aja** in reasonable yields (49–65%). Additionally, electron deficient 5-trifluoromethyl-3-aminopyrazole (**6k**) efficiently underwent standard coupling reaction conditions at both concentrations (0.4 and 0.2 M) affording bicyclic product **8aka** in good yield (76% and

71%, respectively). In contrast, 2-aminoimidazoles are not effective coupling partners, presumably because more forcing conditions are required for aldehyde condensation to give imines. However, we have previously reported that imines from 2-aminoimidazoles can be prepared using $\text{Ti}(\text{OEt})_4$ as an acid catalyst and water scavenger. After isolation, the imines can then be subjected to Rh(III)-catalyzed coupling with sulfoxonium ylides to give imidazopyrimidines in high yields.³

In some drug discovery efforts, pyrazolopyrimidines with only a single substituent on the pyrimidine ring might be desired. We therefore explored formyl sulfoxonium ylide **7i** as a potential input to give pyrazolopyrimidines **8** having only one pyrimidine ring substituent as introduced by the aldehyde (Scheme 5). To our knowledge, formyl sulfoxonium ylides have never previously been employed in a chemical transformation.

Under the optimized one-step three-component reaction conditions, we found that the aldehyde functionality in formyl ylide **7i** effectively competes with the aldehyde input for condensation with the aminopyrazoles. To circumvent this side reaction, a two-step one-pot sequence was instead implemented. The aldehyde **5** and aminopyrazole **6** are first condensed by microwave heating at 150 °C for 30 min in the presence of molecular sieves and PivOH. Formyl ylide **7i**, KOAc, and $[\text{Cp}^*\text{Rh}(\text{MeCN})_3](\text{SbF}_6)_2$ are then added followed by microwave heating at 150 °C for 1 h. It is worth noting that PivOH is added in the first step to catalyze imine formation. Additionally, use of only 1.1 equiv rather than 1.5 equiv of formyl ylide **7i** resulted in moderately higher yields because it minimized competitive imine exchange during the annulation step.

The effect of reaction concentration on this two-step, one-pot protocol was evaluated for the preparation of pyrazolopyrimidine **8aai** from benzaldehyde (**5a**), 4-phenyl-3-aminopyrazole (**6a**), and formyl ylide **7i**. At 0.1 M and 0.2 M concentrations, comparable 80% and 78% yields were obtained, respectively. However, in contrast to the higher yield obtained at higher concentrations for the three-component reaction of β -keto sulfoxonium ylide **7a** (see entries 12 and 13, Table 1), at 0.4 M a significantly lower 63% yield was observed. Therefore, we used a 0.2 M reaction concentration for evaluating the coupling of formyl ylide **7i** with 4-phenyl-3-aminopyrazole **6a** and different aldehydes **5**. Good yields of pyrazolopyrimidines were obtained for benzaldehydes incorporating the electron-deficient trifluoromethyl (**8bai**), electron-rich methoxy (**8cai**), and bromo (**8dai**) functionality. Additionally, pyrazolopyrimidine **8kai** was obtained from 6-chloronicotinaldehyde in 80% yield, and pyrazolopyrimidine **8nai** was obtained from *N*-methyl-4-pyrazolecarboxaldehyde in 66% yield. Disubstituted aminopyrazoles also gave **8aci** and **8adi** in 82% and 72%, respectively.

Unsubstituted aminopyrazole and 5-substituted aminopyrazoles gave higher yields at lower concentrations. At 0.1 M concentration, pyrazolopyrimidines **8aei** and **8afi** were obtained in 30% and 61% yields, respectively.

To directly install an ester group onto the pyrimidine ring of the product we sought to employ ethyl glyoxylate (**5p**) as the aldehyde input (Scheme 6). The standard one-step three-component conditions provided the desired pyrazolopyrimidine **8paa**, but in less than 15%

yield. Due to the reactive nature of ethyl glyoxylate, we speculated that a two-step, one-pot procedure for imine formation followed by Rh(III)-catalyzed annulation might be more successful. Indeed, pyrazolopyrimidine **8paa** was obtained in 82% yield by employing this stepwise approach using only slight excess of ethyl glyoxylate (i.e., 1.1 equiv). It is worth noting that the reaction was completely shut down at high glyoxylate loading (5 equiv). Additionally, this stepwise approach was successfully applied to formyl sulfoxonium ylide **7i** to give pyrazolopyrimidine **8pai** in 81%.

To directly install a methoxy group onto the pyrimidine ring, trimethyl orthoformate (**5q**) was used in place of the aldehyde input **5** (Scheme 7). For this transformation, a one-pot stepwise approach was also the most effective. Consistent with the use of trimethyl orthoformate as a low cost dehydrating agent, the highest yields were achieved by employing 10 equiv of trimethyl orthoformate without the addition of sieves. Under these conditions, pyrazolopyrimidines **8qaa** and **8qai** were obtained in 78% and 36% yields, respectively.

Finally, pyrazolopyrimidine **8naa** was prepared on three-fold larger 1 mmol scale with benchtop set up and a lower catalyst loading of 5 mol % (Scheme 8). It is noteworthy that this lower catalyst loading resulted in only a slight reduction in the yield to 77% at the standard reaction temperature of 150 °C and time of 1 h.

A plausible mechanism for this three-component coupling reaction is depicted in Scheme 9. In accordance to our publication on Rh(III)-catalyzed two-component annulations of *N*-azolo imines with alkynes, diazoketones and sulfoxonium ylides,³ we propose that imine **A**, formed *in situ* from aldehyde **5** and aminopyrazole **6**, undergoes concerted metalation-deprotonation to give rhodacycle **B**. In this publication we reported the X-ray structural characterization of a catalytically competent neutral rhodacycle analogous to **B**.³ Carbene insertion of sulfoxonium ylide **7** with release of dimethyl sulfoxide (DMSO) then provides the six-membered rhodacycle **C**. Protodemetalation releases ketone **D** to regenerate the active Rh(III) catalyst. Finally, under the reaction conditions, ketone **D** undergoes cyclodehydration to afford the pyrazolopyrimidine **8**.

In conclusion, we have reported the Rh(III)-catalyzed three-component coupling of aldehydes **5**, aminopyrazoles **6**, and sulfoxonium ylides **7** to generate diverse pyrazolopyrimidines **8**. This method is operationally convenient with benchtop set up and a short reaction time with microwave heating. A number of aromatic and heteroaromatic aldehydes **5** displaying diverse functionality are effective inputs as are a number of aminopyrazole derivatives **6**. The reaction also proceeds in good yields for a range of aryl, heteroaryl, and alkyl ylides **7**. In addition, the first examples of the application of a formyl sulfoxonium ylide in a metal-catalyzed transformation were implemented for the preparation of pyrazolopyrimidines **8** with only a single substituent on the pyrimidine ring. Ester and methoxy functionalities were also installed directly onto the pyrimidine ring of the bicyclic product by employing ethyl glyoxylate and trimethyl orthoformate in place of the aldehyde input, respectively.

EXPERIMENTAL SECTION

General Information.

Unless otherwise noted, all commercially available reagents were purchased and used as received. Solvents including 1,4-dioxane, tetrahydrofuran (THF), and dichloromethane (CH_2Cl_2) were deoxygenated by sparging with argon. Chlorobenzene was purified by passing through a plug of alumina before use. Microwave reactions were performed using a microwave reactor with an external IR sensor and in a closed reaction vessel. ^1H , ^{13}C , and ^{19}F NMR spectra were recorded on 400 MHz or 600 MHz spectrometers. Chemical shifts [δ (ppm)], coupling constants [J (Hz)], multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, pent = pentet, m = multiplet, br = broad), and integration are reported. Chemical shifts for ^1H and ^{13}C NMR are reported relative to residual undeuterated solvent in CDCl_3 (7.24 ppm for ^1H NMR and 76.99 ppm for ^{13}C NMR) and $(\text{CD}_3)_2\text{SO}$ (2.47 ppm for ^1H NMR and 39.94 ppm for ^{13}C NMR). Flash chromatography was carried out with silica gel with 40–63 μm particle size and with 230–400 mesh. Partial data are provided for IR spectra. Melting points are reported uncorrected. High-resolution mass spectra (HRMS) were obtained using electrospray ionization (ESI) on a time of flight (TOF) mass spectrometer (Yale University) or electron ionization (EI) obtained by the University of Illinois SCS Mass Spectrometry Laboratory.

Preparation of catalysts and reactants.

All aldehydes **5** and aminopyrazoles **6** were purchased and used as received. $[\text{Cp}^*\text{Rh}(\text{MeCN})_3](\text{SbF}_6)_2$ was synthesized according to literature procedures.¹⁴ Sulfoxonium ylides **7a–d** and **7f–h** were synthesized according to literature procedures.^{9f} Sulfoxonium ylides **7e** and **7i** were prepared according to a literature procedure for a related compound with slight modifications.^{9f}

tert-Butyl (4-(dimethyl(oxo)- λ^6 -sulfaneylidene)-3-oxobutyl)carbamate

(7e): Ylide **7e** was prepared from a literature procedure for a related compound with slight modification.^{9f} A mixture of trimethylsulfoxonium iodide (3.52 g, 16.0 mmol, 3.2 equiv) and potassium *tert*-butoxide (1.68 g, 15.0 mmol, 3.0 equiv) in THF (125 mL) was heated to reflux (67 °C) for 2 h under nitrogen. After cooling to rt, to the above mixture was slowly added a solution of 4-nitrophenyl 3-((*tert*-butoxycarbonyl)amino)propanoate (1.55 g, 5.00 mmol, 1.00 equiv) in THF (25 mL). The resulting mixture was stirred at rt for 2 h, filtered through a pad of celite, washed thoroughly with CH_2Cl_2 and concentrated under reduced pressure. Purification by silica gel column chromatography (5% MeOH/ CH_2Cl_2) afforded ylide **7e** (591 mg, 45%) as a yellow solid. mp 114–116 °C. FTIR (neat) 3369, 3001, 1682, 1553, 1523, 1391, 1364, 1276, 1170, 1033, 990, 848, 449 cm^{-1} . ^1H NMR (600 MHz, CDCl_3) δ 5.22 (s, 1H), 4.43 (s, 1H), 3.39 (s, 6H), 3.36 (q, $J = 6.1$ Hz, 2H), 2.37 (t, $J = 6.1$ Hz, 2H), 1.43 (s, 9H). ^{13}C NMR (151 MHz, CDCl_3) δ 189.2, 156.1, 79.0, 70.2, 42.3, 40.0, 37.3, 28.5. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}^{11}\text{H}_{22}\text{NO}_4\text{S}^+$, 264.1264; found 264.1278.

2-(Dimethyl(oxo)- λ^6 -sulfaneylidene)acetaldehyde (7i): Ylide **7i** was prepared from a literature procedure for a related compound with slight modification.^{9f} A mixture of trimethylsulfoxonium iodide (10.6 g, 48.0 mmol, 3.2 equiv) and potassium *tert*-butoxide

(5.05 g, 45.0 mmol, 3.0 equiv) in THF (100 mL) was heated at reflux (67 °C) for 2 h under nitrogen. After cooling to rt, to the above mixture was slowly added a solution of ethyl formate (1.11 g, 15.0 mmol, 1.0 equiv) in THF (10 mL). The resulting mixture was stirred at rt for 1 h, filtered through a pad of celite, washed thoroughly with CH₂Cl₂ and concentrated under reduced pressure. Purification by silica gel column chromatography (10% MeOH/CH₂Cl₂) afforded formyl ylide **7i** as a 97:3 cis/trans ratio of stereoisomers (1.12 g, 62%) as a white solid. mp 71–73 °C. FTIR (neat) 3394, 3082, 3005, 2914, 2788, 1565, 1309, 1296, 1162, 1028, 949, 833, 466 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 9.09 (trans, d, *J* = 9.6 Hz, 0.03H), 8.61 (cis, d, *J* = 2.6 Hz, 1H), 4.61 (trans, d, *J* = 9.6 Hz, 0.03H), 4.35 (cis, d, *J* = 2.6 Hz, 1H), 3.41 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 178.1, 71.9, 42.5. ¹H NMR in (CD₃)₂SO was also obtained to provide a different ratio of sulfoxonium ylide cis/trans isomers (0.74:0.26), which also equilibrated slowly on the NMR time scale as has previously been noted by Kondo and Tunemoto:¹⁵ ¹H NMR (400 MHz, (CD₃)₂SO) δ 8.84 (trans, d, *J* = 9.9 Hz, 0.24H), 8.46 (cis, d, *J* = 2.6 Hz, 0.64H), 4.70 (cis, d, *J* = 2.3 Hz, 0.74H), 4.53 (trans, d, *J* = 9.9 Hz, 0.26H), 3.47 (s, 6H). HRMS (EI): *m/z* [M]⁺ calcd for C₄H₈O₂S, 120.0245; found 120.0244.

General Procedure for Three-Component Reaction of Aminopyrazoles, Aldehydes and β-Keto Sulfoxonium Ylides (0.3 mmol scale).

To a flame-dried 2–5 mL Biotage microwave vial (#351521) charged with a stir bar on the benchtop were added aminopyrazole (0.300 mmol, 1.00 equiv), aldehyde (0.600 mmol, 2.00 equiv), [Cp*Rh(MeCN)₃](SbF₆)₂ (10 mol %, 0.030 mmol, 25 mg), PivOH (1.20 mmol, 4.00 equiv, 123 mg), KOAc (0.30 mmol, 1.0 equiv, 29 mg), 3Å molecular sieves (approximately 300 mg), sulfoxonium ylide (0.450 mmol, 1.50 equiv) and dioxane (0.400 M, 0.750 mL). The vial was capped with a Teflon-lined cap, flushed with nitrogen for about 2 min, and then heated with a Biotage Initiator+ (#356007), which employs an external IR sensor and a closed reaction vessel. The resultant mixture was stirred in the microwave reactor for 1 h at 150 °C using the following settings (absorption level, low; vial type, 2–5 mL; prestirring, 0; initial power, 0; dynamic deflector optimization, ON; pressure: OFF; power, OFF; fixed hold time, ON; stir rate, 600). After cooling to rt, the crude mixture was transferred to a separatory funnel with CH₂Cl₂ (50 mL). PivOH was removed by extracting with satd. NaHCO₃ (100 mL). The organic layer was separated, and the aqueous layer was extracted with CH₂Cl₂ (2 × 50 mL). The combined organic extracts were washed with satd. NaHSO₃ (10 % wt, 100 mL) to remove remaining aldehyde.¹⁶ The organic layer was dried (anhyd. Na₂SO₄) and concentrated under reduced pressure. The product was purified by silica gel column chromatography.

tert-Butyl 4-(3,5-diphenylpyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (**8aaa**):

The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a**, 61.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5a** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a**. Purification by silica gel column chromatography (10–30% Et₂O/hexanes) afforded **8aaa** (112 mg, 82%) as a yellow solid. ¹H and ¹³C NMR spectra matched with previously reported literature.³ ¹H NMR (400 MHz, CDCl₃) δ 8.43 (s, 1H), 8.22–8.09 (m, 4H), 7.59–7.39 (m, 5H), 7.26 (t, *J* = 7.3 Hz, 1H), 7.12 (s, 1H), 4.51–4.14 (m, 2H), 3.78 (tt, *J* = 12.2, 3.4 Hz, 1H), 2.98 (m, 2H),

2.32–2.11 (m, 2H), 1.86–1.65 (m, 2H), 1.49 (s, 9H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.9, 154.6, 152.1, 145.1, 142.3, 137.5, 132.3, 130.4, 128.9, 128.7, 127.3, 126.2, 126.1, 110.7, 101.4, 79.8, 43.7, 36.6, 29.4, 28.5.

tert-Butyl 4-(3-phenyl-5-(4-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8baa): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a**, 82.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5b** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a**. Purification by silica gel column chromatography (10–30% Et_2O /hexanes) afforded **8baa** (123 mg, 78%) as a yellow foam. FTIR (neat) 1681, 1422, 1314, 1237, 1157, 1113, 1063, 768, 725, 692 cm^{-1} . ^1H NMR (400 MHz, CDCl_3) δ 8.46 (s, 1H), 8.26 (d, $J = 8.2$ Hz, 2H), 8.18–8.09 (m, 2H), 7.77 (d, $J = 8.2$ Hz, 2H), 7.52–7.43 (m, 2H), 7.32–7.26 (m, 1H), 7.12 (s, 1H), 4.51–4.17 (m, 2H), 3.79 (tt, $J = 12.1, 3.3$ Hz, 1H), 3.10–2.87 (m, 2H), 2.28–2.15 (m, 2H), 1.85–1.69 (m, 2H), 1.49 (s, 9H). ^{13}C NMR (101 MHz, CDCl_3) δ 154.6, 154.2, 152.6, 144.9, 142.6, 140.8, 132.0, 131.9 (q, $J = 32.6$ Hz), 128.8, 127.6, 126.34, 126.30, 125.8 (q, $J = 3.8$ Hz), 124.0 (q, $J = 272.2$ Hz), 111.3, 101.3, 79.9, 43.7, 36.7, 29.3, 28.4. ^{19}F NMR (376 MHz, CDCl_3) δ –62.8. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{29}\text{H}_{30}\text{F}_3\text{N}_4\text{O}_2^+$, 523.2315; found 523.2291.

tert-Butyl 4-(5-(4-methoxyphenyl)-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8caa): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a**, 73.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5c** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a**. Purification by silica gel column chromatography (10–30% Et_2O /hexanes) afforded **8caa** (116 mg, 80%) as a yellow solid. mp 191–193 $^\circ\text{C}$. FTIR (neat) 1693, 1602, 1426, 1388, 1250, 1173, 1128, 1032, 945, 823, 699, 563, 509 cm^{-1} . ^1H NMR (400 MHz, CDCl_3) δ 8.40 (s, 1H), 8.23–8.05 (m, 4H), 7.45 (t, $J = 7.8$ Hz, 2H), 7.25 (t, $J = 7.3$ Hz, 1H), 7.11–6.90 (m, 3H), 4.49–4.17 (m, 2H), 3.88 (s, 3H), 3.75 (tt, $J = 12.2, 3.4$ Hz, 1H), 2.98 (broad t, $J = 10.6$ Hz, 2H), 2.28–2.15 (m, 2H), 1.86–1.64 (m, 2H), 1.49 (s, 9H). ^{13}C NMR (101 MHz, CDCl_3) δ 161.6, 155.5, 154.7, 151.9, 145.1, 142.2, 132.5, 130.0, 128.8, 128.7, 126.2, 125.9, 114.3, 110.3, 100.9, 79.8, 55.4, 43.8, 36.6, 29.4, 28.5. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{29}\text{H}_{33}\text{N}_4\text{O}_3^+$, 485.2547; found 485.2547.

tert-Butyl 4-(5-(3-bromophenyl)-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8daa): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a**, 70.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5d** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a**. Purification by silica gel column chromatography (10–40% Et_2O /hexanes) afforded **8daa** (114 mg, 71%) as a yellow solid. mp 168–171 $^\circ\text{C}$. FTIR (neat) 1682, 1563, 1429, 1234, 1166, 1126, 1078, 946, 795, 760, 623, 533 cm^{-1} . ^1H NMR (400 MHz, CDCl_3) δ 8.44 (s, 1H), 8.26 (t, $J = 1.8$ Hz, 1H), 8.16–8.11 (m, 2H), 8.09 (ddd, $J = 7.9, 1.8, 1.0$ Hz, 1H), 7.61 (ddd, $J = 8.0, 2.0, 1.0$ Hz, 1H), 7.47 (t, $J = 7.8$ Hz, 2H), 7.39 (t, $J = 7.9$ Hz, 1H), 7.31–7.25 (m, 1H), 7.06 (s, 1H), 4.55–4.20 (m, 2H), 3.78 (tt, $J = 12.1, 3.4$ Hz, 1H), 3.15–2.77 (m, 2H), 2.28–2.16 (m, 2H), 1.84–1.66 (m, 2H), 1.49 (s, 9H). ^{13}C NMR (101 MHz, CDCl_3) δ 154.6, 154.2, 152.5, 144.9, 142.6, 139.5, 133.2, 132.1, 130.4, 130.3, 128.8, 126.3, 126.3,

125.9, 123.1, 111.1, 101.2, 79.8, 43.9, 36.7, 29.3, 28.5. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{28}H_{30}BrN_4O_2^+$, 533.1547; found 533.1573.

tert-Butyl 4-(5-(2-chlorophenyl)-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8eaa): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a**, 67.6 μ L (0.600 mmol, 2.00 equiv) of aldehyde **5e** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a**. Purification by silica gel column chromatography (5–20% EtOAc/hexanes) afforded **8eaa** (67.5 mg, 46%) as a yellow solid. mp 194–196 °C. FTIR (neat) 1688, 1609, 1564, 1425, 1231, 1163, 1126, 946, 758, 696, 516 cm^{-1} . 1H NMR (400 MHz, $CDCl_3$) δ 8.46 (s, 1H), 8.14–8.05 (m, 2H), 7.81–7.74 (m, 1H), 7.55–7.47 (m, 1H), 7.46–7.37 (m, 4H), 7.26–7.20 (m, 1H), 7.10 (s, 1H), 4.49–4.20 (m, 2H), 3.79 (tt, $J = 12.1, 3.3$ Hz, 1H), 3.08–2.89 (m, 2H), 2.30–2.17 (m, 2H), 1.80–1.65 (m, 2H), 1.47 (s, 9H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 156.1, 154.7, 151.1, 144.9, 142.2, 137.8, 132.3, 132.1, 131.8, 130.6, 130.4, 128.7, 127.2, 126.3, 126.2, 111.3, 106.0, 79.8, 43.8, 36.5, 29.2, 28.4. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{28}H_{30}ClN_4O_2^+$, 489.2052; found 489.2042.

tert-Butyl 4-(5-(4-(methoxycarbonyl)phenyl)-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8faa): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a**, 98.5 mg (0.600 mmol, 2.00 equiv) of aldehyde **5f** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a**. Purification by silica gel column chromatography (2–10% EtOAc/ CH_2Cl_2) afforded **8faa** (108 mg, 70%) as a yellow solid. mp > 240 °C. FTIR (neat) 1716, 1692, 1406, 1274, 1233, 1166, 1119, 1109, 947, 767, 699 cm^{-1} . 1H NMR (400 MHz, $CDCl_3$) δ 8.45 (s, 1H), 8.26–8.12 (m, 6H), 7.47 (t, $J = 7.7$ Hz, 2H), 7.28 (t, $J = 7.4$ Hz, 1H), 7.14 (s, 1H), 4.49–4.22 (m, 2H), 3.95 (s, 3H), 3.78 (tt, $J = 12.1, 3.4$ Hz, 1H), 3.09–2.86 (m, 2H), 2.29–2.16 (m, 2H), 1.86–1.68 (m, 2H), 1.49 (s, 9H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 166.6, 154.6, 154.5, 152.5, 144.9, 142.6, 141.4, 132.1, 131.5, 130.1, 128.8, 127.2, 126.3, 111.3, 101.4, 79.8, 52.3, 43.8, 36.7, 29.3, 28.5. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{30}H_{33}N_4O_4^+$, 513.2496; found 513.2520.

4-(7-(1-(tert-Butoxycarbonyl)piperidin-4-yl)-3-phenylpyrazolo[1,5-a]pyrimidin-5-yl)benzoic acid (8gaa): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a**, 90.1 mg (0.600 mmol, 2.00 equiv) of aldehyde **5g** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a** with slight modification in reaction concentration (0.200 M, 1.50 mL of dioxane) and work-up procedure; the reaction mixture after diluting with CH_2Cl_2 was washed with citric acid monohydrate (1 % wt, 100 mL) instead of satd. $NaHCO_3$. Purification by silica gel column chromatography (10–50% EtOAc/ CH_2Cl_2) afforded **8gaa** (92.7 mg, 62%) as a yellow solid. mp > 240 °C. FTIR (neat) 1716, 1615, 1439, 1366, 1243, 1163, 1131, 1113, 787, 692, 663, 515, 526 cm^{-1} . 1H NMR (600 MHz, $(CD_3)_2SO$) δ 13.12 (br s, 1H), 8.76 (s, 1H), 8.43 (d, $J = 8.5$ Hz, 2H), 8.23–8.16 (m, 2H), 8.08 (d, $J = 8.5$ Hz, 2H), 7.62 (s, 1H), 7.45 (d, $J = 7.8$ Hz, 2H), 7.26–7.21 (m, 1H), 4.27–4.05 (m, 2H), 3.72 (tt, $J = 12.1, 3.4$ Hz, 1H), 3.08–2.73 (m, 2H), 2.13–1.99 (m, 2H), 1.89–1.72 (m, 2H), 1.41 (s, 9H). ^{13}C NMR (151 MHz, $(CD_3)_2SO$) δ 167.4, 154.8, 154.1, 153.2, 144.6, 143.1, 141.0, 132.7, 132.5, 130.2,

129.2, 128.0, 126.4, 126.2, 110.2, 102.8, 79.2, 44.2, 43.2, 36.7, 29.0, 28.6. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{29}H_{31}N_4O_4^+$, 499.2340; found 499.2358.

tert-Butyl 4-(5-(4-acetamidophenyl)-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8haa): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a**, 97.9 mg (0.600 mmol, 2.00 equiv) of aldehyde **5h** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a**. Purification by silica gel column chromatography (10–40% EtOAc/CH₂Cl₂) afforded **8haa** (128 mg, 83%) as a yellow solid. mp 130–133 °C. FTIR (neat) 1667, 1596, 1522, 1387, 1366, 1235, 1161, 1124, 945, 768, 693, 507 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 8.39 (s, 1H), 8.16–8.06 (m, 4H), 7.73 (br s, 1H), 7.66 (d, $J = 8.4$ Hz, 2H), 7.44 (t, $J = 7.8$ Hz, 2H), 7.24 (t, $J = 7.4$ Hz, 1H), 7.02 (s, 1H), 4.45–4.19 (m, 2H), 3.71 (tt, $J = 12.2, 3.4$ Hz, 1H), 3.07–2.81 (m, 2H), 2.21 (s, 3H), 2.25–2.14 (m, 2H), 1.82–1.62 (m, 2H), 1.48 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 168.6, 155.0, 154.7, 152.0, 145.0, 142.2, 140.0, 132.9, 132.3, 128.7, 128.1, 126.1, 126.0, 119.7, 110.5, 101.0, 79.9, 43.9, 36.6, 29.3, 28.5, 24.7. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{30}H_{34}N_5O_3^+$, 512.2656; found 512.2661.

tert-Butyl 4-(3-phenyl-5-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8iaa): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a**, 56.5 μL (0.600 mmol, 2.00 equiv) of aldehyde **5i** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a**. Purification by silica gel column chromatography (10–40% EtOAc/CH₂Cl₂) afforded **8iaa** (78.8 mg, 58%) as a yellow solid. mp 169–171 °C. FTIR (neat) 1682, 1604, 1566, 1428, 1387, 1295, 1234, 1166, 1129, 942, 817, 768, 692 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 8.79 (d, $J = 5.6$ Hz, 2H), 8.47 (s, 1H), 8.16–8.08 (m, 2H), 8.06–7.96 (m, 2H), 7.47 (t, $J = 7.8$ Hz, 2H), 7.33–7.24 (m, 1H), 7.12 (s, 1H), 4.51–4.22 (m, 2H), 3.80 (tt, $J = 12.1, 3.3$ Hz, 1H), 3.10–2.89 (m, 2H), 2.30–2.19 (m, 2H), 1.86–1.68 (m, 2H), 1.48 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 154.6, 153.0, 152.9, 150.7, 144.8, 144.4, 142.8, 131.8, 128.8, 126.5, 126.4, 121.1, 111.7, 101.0, 79.9, 43.8, 36.7, 29.3, 28.4. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{27}H_{30}N_5O_2^+$, 456.2394; found 456.2401.

tert-Butyl 4-(5-(6-acetamidopyridin-3-yl)-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8jaa): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a**, 98.5 mg (0.600 mmol, 2.00 equiv) of aldehyde **5j** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a**. Purification by silica gel column chromatography (10–40% EtOAc/CH₂Cl₂) afforded **8jaa** (118 mg, 77%) as a yellow solid. mp > 240 °C. FTIR (neat) 1696, 1598, 1520, 1384, 1364, 1305, 1232, 1167, 1122, 9945, 767, 691, 509 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 9.07 (d, $J = 1.8$ Hz, 1H), 8.47 (s, 1H), 8.46–8.40 (m, 2H), 8.39–8.31 (m, 1H), 8.15–8.07 (m, 2H), 7.45 (t, $J = 7.8$ Hz, 2H), 7.29–7.22 (m, 1H), 7.04 (s, 1H), 4.47–4.18 (m, 2H), 3.77 (tt, $J = 12.1, 3.3$ Hz, 1H), 3.06–2.88 (m, 2H), 2.26 (s, 3H), 2.29–2.17 (m, 2H), 1.82–1.66 (m, 2H), 1.48 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 168.8, 154.6, 152.9, 152.6, 152.6, 147.1, 144.9, 142.5, 137.1, 132.1, 129.1, 128.7, 126.3, 126.2, 113.5, 110.9, 100.5, 79.8, 43.7, 36.7, 29.3, 28.5, 24.8. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{29}H_{33}N_6O_3^+$, 513.2609; found 513.2619.

tert-Butyl 4-(5-(6-chloropyridin-3-yl)-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8kaa): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a**, 84.9 mg (0.600 mmol, 2.00 equiv) of aldehyde **5k** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a**. Purification by silica gel column chromatography (2–10% EtOAc/CH₂Cl₂) afforded **8kaa** (96.3 mg, 66%) as a yellow solid. mp 199–202 °C. FTIR (neat) 1692, 1567, 1426, 1235, 1164, 1129, 1105, 945, 826, 771, 692, 497, 474 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 9.11 (d, *J* = 2.1 Hz, 1H), 8.45 (s, 1H), 8.43 (dd, *J* = 8.3, 2.5 Hz, 1H), 8.14–8.05 (m, 2H), 7.52–7.40 (m, 3H), 7.32–7.25 (m, 1H), 7.05 (s, 1H), 4.49–4.20 (m, 2H), 3.78 (tt, *J* = 12.1, 3.3 Hz, 1H), 3.09–2.83 (m, 2H), 2.31–2.13 (m, 2H), 1.84–1.68 (m, 2H), 1.48 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 154.6, 153.1, 153.0, 152.0, 148.5, 144.8, 142.7, 137.3, 132.0, 131.8, 128.77, 126.5, 126.3, 124.5, 111.4, 100.6, 79.9, 43.7, 36.8, 29.2, 28.4. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₇H₂₉ClN₅O₂⁺, 490.2004; found 490.2022.

tert-Butyl 4-(5-(furan-2-yl)-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8laa): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a**, 49.7 μL (0.600 mmol, 2.00 equiv) of aldehyde **5l** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a**. Purification by silica gel column chromatography (10–40% Et₂O/hexanes) afforded **8laa** (108 mg, 81%) as a yellow solid. mp 201–203 °C. FTIR (neat) 1681, 1610, 1426, 1292, 1229, 1167, 1005, 937, 765, 743, 515 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 8.40 (s, 1H), 8.15–8.07 (m, 2H), 7.59 (dd, *J* = 1.8, 0.8 Hz, 1H), 7.44 (t, *J* = 7.8 Hz, 2H), 7.31 (dd, *J* = 3.5, 0.8 Hz, 1H), 7.29–7.20 (m, 1H), 7.10 (s, 1H), 6.59 (dd, *J* = 3.5, 1.8 Hz, 1H), 4.48–4.21 (m, 2H), 3.74 (tt, *J* = 12.1, 3.4 Hz, 1H), 3.06–2.86 (m, 2H), 2.27–2.13 (m, 2H), 1.84–1.64 (m, 2H), 1.48 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 154.6, 152.5, 152.3, 147.7, 144.9, 144.5, 142.3, 132.3, 128.7, 126.2, 126.1, 112.7, 111.5, 110.4, 100.1, 79.7, 43.8, 36.5, 29.3, 28.5. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₆H₂₉N₄O₃⁺, 445.2240; found 445.2263.

tert-Butyl 4-(3-phenyl-5-(thiophen-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8maa): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a**, 52.6 μL (0.600 mmol, 2.00 equiv) of aldehyde **5m** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a**. Purification by silica gel column chromatography (5–25% EtOAc/hexanes) afforded **8maa** (117 mg, 85%) as a yellow solid. mp 182–185 °C. FTIR (neat) 1691, 1672, 1608, 1418, 1366, 1291, 1237, 1163, 1134, 1068, 762, 691, 515 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 8.40 (s, 1H), 8.17–8.09 (m, 2H), 8.03 (dd, *J* = 3.0, 1.3 Hz, 1H), 7.84 (dd, *J* = 5.1, 1.3 Hz, 1H), 7.50–7.40 (m, 3H), 7.30–7.22 (m, 1H), 6.96 (s, 1H), 4.50–4.17 (m, 2H), 3.75 (tt, *J* = 12.1, 3.4 Hz, 1H), 3.08–2.84 (m, 2H), 2.27–2.17 (m, 2H), 1.83–1.64 (m, 2H), 1.49 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 154.7, 152.1, 151.9, 144.9, 142.3, 140.9, 132.4, 128.7, 126.7, 126.7, 126.2, 126.0, 125.9, 110.5, 101.7, 79.8, 43.8, 36.5, 29.4, 28.5. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₆H₂₉N₄O₂S⁺, 461.2006; found 461.2000.

tert-Butyl 4-(5-(1-methyl-1H-pyrazol-4-yl)-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8naa): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a**, 66.1

mg (0.600 mmol, 2.00 equiv) of aldehyde **5n** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a**. Purification by silica gel column chromatography (5–30% EtOAc/CH₂Cl₂) afforded **8naa** (114 mg, 83%) as a light yellow solid. mp > 240 °C. FTIR (neat) 1684, 1616, 1551, 1427, 1235, 1168, 1126, 999, 863, 767, 751, 695, 516 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 8.37 (s, 1H), 8.12–8.09 (m, 2H), 8.07 (s, 1H), 8.05 (s, 1H), 7.47–7.43 (m, 2H), 7.30–7.21 (m, 1H), 6.78 (s, 1H), 4.51–4.14 (m, 2H), 3.99 (s, 3H), 3.73 (tt, *J* = 12.2, 3.4 Hz, 1H), 3.12–2.86 (m, 2H), 2.27–2.15 (m, 2H), 1.79–1.65 (m, 2H), 1.49 (s, 9H). ¹³C NMR (151 MHz, CDCl₃) δ 154.6, 152.0, 150.9, 145.1, 142.2, 138.4, 132.5, 130.1, 128.7, 126.1, 125.9, 122.5, 109.7, 101.4, 79.8, 44.1, 43.4, 39.4, 36.4, 29.4, 28.5. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₆H₃₁N₆O₂⁺, 459.2503; found 459.2507.

tert-Butyl 4-(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8oaa): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a**, 26.5 mg (0.600 mmol, 2.00 equiv) of aldehyde **5o** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a** with slight modification in reaction concentration (0.200 M, 1.50 mL of dioxane) and in order of addition; after nitrogen flush, acetaldehyde was added in one portion as a solution in dioxane (1.50 mL) via syringe. Purification by preparative TLC plate (UV₂₅₄, 20×20 cm, 1000 micron; 20:80:1 EtOAc/hexanes/Et₃N) afforded **8oaa** (15.2 mg, 13%) as a white solid. mp 194–196 °C. FTIR (neat) 1679, 1605, 1566, 1441, 1427, 1365, 1289, 1234, 1156, 1125, 864, 771, 699 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 8.35 (s, 1H), 8.10–7.95 (m, 2H), 7.41 (t, *J* = 7.8 Hz, 2H), 7.27–7.18 (m, 1H), 6.51 (s, 1H), 4.45–4.15 (m, 2H), 3.69 (tt, *J* = 12.1, 3.4 Hz, 1H), 2.94 (t, *J* = 13.2 Hz, 2H), 2.61 (s, 3H), 2.21–2.10 (m, 2H), 1.69–1.58 (m, 2H), 1.47 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 159.1, 154.6, 151.3, 144.9, 141.9, 132.4, 128.7, 126.2, 126.0, 109.6, 105.1, 79.8, 43.7, 36.2, 29.3, 28.4, 25.2. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₃H₂₉N₄O₂⁺, 393.2285; found 393.2289.

7-Isopropyl-3,5-diphenylpyrazolo[1,5-a]pyrimidine (8aab): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a**, 61.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5a**, and 78.8 mg (0.486 mmol, 1.5 equiv) of ylide **7b**. Purification by silica gel column chromatography (25–50% CH₂Cl₂/hexanes) afforded **8aab** (74.1 mg, 79%) as a yellow solid. mp 105–107 °C. FTIR (neat) 1606, 1564, 1523, 1492, 1386, 1253, 1201, 1176, 828, 763, 692, 657, 603 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 8.48 (s, 1H), 8.23–8.20 (m, 4H), 7.58–7.47 (m, 5H), 7.29 (tt, *J* = 7.3, 1.2 Hz, 1H), 7.20 (s, 1H), 3.95 (hept, *J* = 6.9 Hz, 1H), 1.54 (d, *J* = 7.0 Hz, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 155.9, 155.2, 145.2, 142.3, 137.7, 132.6, 130.2, 128.9, 128.7, 127.4, 126.2, 126.0, 110.5, 100.9, 28.7, 20.1. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₁H₂₀N₃⁺, 314.1652; found 314.1654.

7-Isobutyl-3,5-diphenylpyrazolo[1,5-a]pyrimidine (8aac): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a**, 61.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5a**, and 80.1 mg (0.454 mmol, 1.5 equiv) of ylide **7c**. Purification by silica gel column chromatography (25–50% CH₂Cl₂/hexanes) afforded **8aac** (85.0 mg, 87%) as a yellow solid. mp 114–116 °C. FTIR (neat) 1607, 1564, 1523, 1389, 1197, 763, 685, 643, 595, 516 cm⁻¹. ¹H NMR (600 MHz,

CDCl₃) δ 8.47 (s, 1H), 8.24–8.18 (m, 4H), 7.59–7.46 (m, 5H), 7.31–7.26 (m, 1H), 7.16 (s, 1H), 3.12 (d, *J* = 7.3 Hz, 2H), 2.54–2.43 (m, 1H), 1.09 (d, *J* = 6.6 Hz, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 155.6, 149.1, 145.4, 142.6, 137.7, 132.7, 130.4, 129.0, 128.8, 127.5, 126.3, 126.1, 110.6, 104.9, 40.2, 26.0, 22.8. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₂H₂₂N₃⁺, 328.1808; found 328.1803.

7-Methyl-3,5-diphenylpyrazolo[1,5-a]pyrimidine (8aad): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a**, 61.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5a** and 65.2 mg (0.486 mmol, 1.5 equiv) of ylide **7d**. Purification by silica gel column chromatography (50% CH₂Cl₂/hexanes) afforded **8aad** (68.5 mg, 80%) as a yellow solid. mp 142–144 °C. FTIR (neat) 1605, 1563, 1369, 1200, 765, 692, 640, 596, 515 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 8.46 (s, 1H), 8.23–8.10 (m, 4H), 7.56–7.41 (m, 5H), 7.31–7.22 (m, 1H), 7.17 (s, 1H), 2.84 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 155.5, 146.0, 145.0, 142.5, 137.4, 132.5, 130.3, 128.9, 128.7, 127.3, 126.2, 126.0, 110.6, 105.0, 17.5. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₁₉H₁₆N₃⁺, 286.1339; found 286.1338.

tert-Butyl (2-(3,5-diphenylpyrazolo[1,5-a]pyrimidin-7-yl)ethyl)carbamate (8aae): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a**, 61.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5a** and 129 mg (0.488, 1.5 equiv mmol) of ylide **7e**. Purification by silica gel column chromatography (25% EtOAc/hexanes) afforded **8aae** (118 mg, 94%) as a yellow solid. mp 153–155 °C. FTIR (neat) 1698, 1565, 1530, 1271, 1160, 1137, 765, 685, 596, 495 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 8.44 (s, 1H), 8.25–8.13 (m, 4H), 7.56–7.45 (m, 5H), 7.31–7.26 (m, 2H), 4.93 (br s, NH, 1H), 3.76 (q, *J* = 6.6 Hz, 2H), 3.46 (t, *J* = 6.8 Hz, 2H), 1.42 (s, 9H). ¹³C NMR (151 MHz, CDCl₃) δ 155.9, 155.7, 146.6, 145.1, 142.5, 137.2, 132.3, 130.4, 128.9, 128.7, 127.4, 126.2, 126.1, 110.8, 104.9, 79.6, 37.5, 31.6, 28.3. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₅H₂₇N₄O₂⁺, 415.2129; found 415.2138.

7-(4-Methoxyphenyl)-3,5-diphenylpyrazolo[1,5-a]pyrimidine (8aaf): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a**, 61.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5a** and 107 mg (0.473 mmol, 1.5 equiv) of ylide **7f**. Purification by silica gel column chromatography (25–50% CH₂Cl₂/hexanes) afforded **8aaf** (101 mg, 89%) as a yellow solid. ¹H and ¹³C NMR spectra matched with previously reported literature.³ ¹H NMR (600 MHz, CDCl₃) δ 8.49 (s, 1H), 8.28–8.20 (m, 4H), 8.13–8.07 (m, 2H), 7.58–7.47 (m, 5H), 7.38 (s, 1H), 7.32–7.27 (m, 1H), 7.15–7.09 (m, 2H), 3.92 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 161.9, 156.0, 146.9, 146.2, 143.0, 137.7, 132.7, 131.1, 130.5, 129.1, 128.9, 127.5, 126.5, 126.2, 123.8, 114.3, 110.6, 104.5, 55.7.

3,5-Diphenyl-7-(4-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine (8aag): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a**, 61.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5a** and 124 mg (0.469 mmol, 1.5 equiv) of ylide **7g**. Purification by silica gel column chromatography (25–50% CH₂Cl₂/hexanes) afforded **8aag** (109 mg, 87%) as a yellow solid.

^1H , ^{13}C and ^{19}F NMR spectra matched with previously reported literature.³ ^1H NMR (400 MHz, CDCl_3) δ 8.48 (s, 1H), 8.27–8.16 (m, 6H), 7.87 (d, J = 8.2 Hz, 2H), 7.60–7.47 (m, 5H), 7.39 (s, 1H), 7.32 (t, J = 7.4 Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 156.0, 146.0, 145.5, 143.2, 137.2, 135.0, 132.9 (q, J = 32.9 Hz), 132.2, 130.8, 129.9, 129.2, 128.9, 127.5, 126.6, 126.5, 125.9 (q, J = 3.7 Hz), 123.9 (q, J = 272.5 Hz), 111.3, 105.5. ^{19}F NMR (376 MHz, CDCl_3) δ – 63.0.

3,5-Diphenyl-7-(thiophen-2-yl)pyrazolo[1,5-a]pyrimidine (8aah): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a**, 61.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5a** and 91.1 mg (0.450, 1.50 equiv mmol) of ylide **7h**. Purification by silica gel column chromatography (25–50% CH_2Cl_2 /hexanes) afforded **8aah** (89.8 mg, 85%) as a red solid. mp 162–164 °C. FTIR (neat) 1603, 1554, 1529, 1494, 1380, 820, 763, 715, 690, 668, 491 cm^{-1} . ^1H NMR (600 MHz, CDCl_3) δ 8.56 (s, 1H), 8.39–8.37 (m, 1H), 8.26–8.19 (m, 4H), 7.74–7.71 (m, 1H), 7.69 (s, 1H), 7.59–7.47 (m, 5H), 7.33–7.27 (m, 2H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.4, 146.1, 142.6, 140.2, 137.6, 132.5, 132.1, 131.9, 131.3, 130.4, 129.0, 128.8, 127.7, 127.4, 126.5, 126.2, 110.7, 101.7. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{16}\text{N}_3\text{S}^+$, 354.1059; found 354.1063.

tert-Butyl 4-(3-methyl-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8aba): The reaction was performed according to the general procedure employing 29.2 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6b**, 61.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5a** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a**. Purification by silica gel column chromatography (2–5% $\text{EtOAc}/\text{CH}_2\text{Cl}_2$) afforded **8aba** (83.6 mg, 71%) as a light yellow solid. mp 150–152 °C. FTIR (neat) 1673, 1616, 1430, 1381, 1238, 1162, 1125, 968, 773, 690, 639, 538 cm^{-1} . ^1H NMR (400 MHz, CDCl_3) δ 8.10–8.04 (m, 2H), 7.95 (s, 1H), 7.53–7.41 (m, 3H), 7.01 (s, 1H), 4.47–4.15 (m, 2H), 3.73 (tt, J = 12.1, 3.3 Hz, 1H), 3.07–2.83 (m, 2H), 2.42 (s, 3H), 2.27–2.14 (m, 2H), 1.80–1.61 (m, 2H), 1.47 (s, 9H). ^{13}C NMR (101 MHz, CDCl_3) δ 154.6, 154.6, 151.5, 146.5, 144.5, 137.9, 130.0, 128.8, 127.2, 106.2, 100.8, 79.7, 43.7, 36.4, 29.3, 28.5, 7.7. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{29}\text{N}_4\text{O}_2^+$, 393.2285; found 393.2298.

tert-Butyl 4-(2-methyl-3,5-diphenylpyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8aca): The reaction was performed according to the general procedure employing 52.0 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6c**, 61.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5a** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a**. Purification by silica gel column chromatography (5–20% acetone/hexanes) afforded **8aca** (84.4 mg, 60%) as a light yellow solid. mp 156–158 °C. FTIR (neat) 1680, 1606, 1420, 1364, 1233, 1165, 1125, 745, 768, 696, 621 cm^{-1} . ^1H NMR (600 MHz, CDCl_3) δ 8.11 (d, J = 6.7 Hz, 2H), 7.85 (d, J = 6.8 Hz, 2H), 7.53–7.40 (m, 5H), 7.31 (t, J = 7.4 Hz, 1H), 7.06 (s, 1H), 4.50–4.20 (s, 2H), 3.80 (tt, J = 12.2, 3.4 Hz, 1H), 3.12–2.89 (bs, 2H), 2.68 (s, 3H), 2.35–2.16 (m, 2H), 1.82–1.70 (m, 2H), 1.50 (s, 9H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.6, 154.7, 152.2, 151.4, 146.3, 137.6, 132.8, 130.1, 128.8, 128.8, 128.4, 127.2, 126.0, 109.4, 100.9, 79.8, 44.2, 43.4, 36.3, 29.4, 28.5, 14.7. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{29}\text{H}_{33}\text{N}_4\text{O}_2^+$, 469.2598; found 469.2601.

tert-Butyl 4-(2-ethyl-3-methyl-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8ada): The reaction was performed according to the general procedure employing 37.6 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6d**, 61.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5a** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a**. Purification by silica gel column chromatography (5–20% EtOAc/hexanes) afforded **8ada** (82.0 mg, 65%) as a light yellow solid. mp 120–122 °C. FTIR (neat) 1689, 1617, 1425, 1364, 1292, 1232, 1165, 1119, 770, 688 cm^{-1} . ^1H NMR (600 MHz, CDCl_3) δ 8.13–8.01 (m, 2H), 7.53–7.38 (m, 3H), 6.92 (s, 1H), 4.50–4.14 (m, 2H), 3.74 (tt, $J = 12.1, 3.4$ Hz, 1H), 3.08–2.90 (m, 2H), 2.85 (q, $J = 7.6$ Hz, 2H), 2.36 (s, 3H), 2.26–2.13 (m, 2H), 1.80–1.63 (m, 2H), 1.48 (s, 9H), 1.33 (t, $J = 7.6$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 158.4, 154.7, 154.3, 151.2, 147.0, 138.2, 129.8, 128.8, 127.1, 102.9, 99.9, 79.7, 44.1, 43.4, 36.2, 29.3, 28.5, 21.0, 13.7, 7.0. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{33}\text{N}_4\text{O}_2^+$, 421.2598; found 421.2604.

tert-Butyl 4-(5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8aea): The reaction was performed according to the general procedure employing 25.0 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6e**, 61.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5a** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a** with slight modification in reaction concentration (0.200 M, 1.50 mL of dioxane). Purification by silica gel column chromatography (5–20% EtOAc/ CH_2Cl_2) afforded **8aea** (69.9 mg, 62%) as an off-white foam. FTIR (neat) 1670, 1613, 1432, 1240, 1163, 1129, 1002, 903, 771, 693, 640, 540 cm^{-1} . ^1H NMR (400 MHz, CDCl_3) δ 8.11 (d, $J = 2.4$ Hz, 1H), 8.08–7.97 (m, 2H), 7.54–7.40 (m, 3H), 7.06 (s, 1H), 6.71 (d, $J = 2.3$ Hz, 1H), 4.47–4.21 (m, 2H), 3.77 (tt, $J = 12.2, 3.2$ Hz, 1H), 3.06–2.87 (m, 2H), 2.27–2.16 (m, 2H), 1.81–1.66 (m, 2H), 1.47 (s, 9H). ^{13}C NMR (101 MHz, CDCl_3) δ 156.2, 154.6, 152.0, 148.9, 144.6, 137.6, 130.2, 128.9, 127.2, 101.5, 97.1, 79.7, 43.7, 36.6, 29.3, 28.4. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{27}\text{N}_4\text{O}_2^+$, 379.2129; found 379.2131.

tert-Butyl 4-(2-(tert-butyl)-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8afa): The reaction was performed according to the general procedure employing 41.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6f**, 61.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5a** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a** with slight modification in reaction concentration (0.200 M, 1.50 mL of dioxane). Purification by silica gel column chromatography (2–5% EtOAc/ CH_2Cl_2) afforded **8afa** (95.0 mg, 73%) as a white foam. FTIR (neat) 2961, 1690, 1610, 1533, 1449, 1364, 1233, 1164, 1120, 771, 692, 591 cm^{-1} . ^1H NMR (400 MHz, CDCl_3) δ 8.10–7.92 (m, 2H), 7.54–7.38 (m, 3H), 6.96 (s, 1H), 6.54 (s, 1H), 4.46–4.19 (m, 2H), 3.73 (tt, $J = 12.1, 3.4$ Hz, 1H), 3.06–2.86 (m, 2H), 2.28–2.16 (m, 2H), 1.82–1.65 (m, 2H), 1.48 (s, 9H), 1.41 (s, 9H). ^{13}C NMR (101 MHz, CDCl_3) δ 167.7, 155.5, 154.7, 151.5, 149.2, 138.0, 129.9, 128.8, 127.1, 100.5, 92.9, 79.7, 43.9, 36.7, 32.9, 30.4, 29.0, 28.5. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{26}\text{H}_{35}\text{N}_4\text{O}_2^+$, 435.2755; found 435.2760.

tert-Butyl 4-(2-methyl-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8aga): The reaction was performed according to the general procedure employing 29.2 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6g**, 61.0 μL (0.600 mmol,

2.00 equiv) of aldehyde **5a** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a** with slight modification in reaction concentration (0.200 M, 1.50 mL of dioxane). Purification by silica gel column chromatography (2–10% EtOAc/CH₂Cl₂) afforded **8aga** (57.6 mg, 49%) as an off-white solid. mp 165–167 °C. FTIR (neat) 1685, 1610, 1533, 1470, 1415, 1364, 1235, 1156, 999, 867, 772, 695, 586 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 8.05–7.99 (m, 2H), 7.52–7.41 (m, 3H), 6.97 (s, 1H), 6.48 (s, 1H), 4.48–4.13 (m, 2H), 3.76 (tt, *J* = 12.2, 3.4 Hz, 1H), 3.12–2.84 (m, 2H), 2.52 (s, 3H), 2.25–2.15 (m, 2H), 1.80–1.62 (m, 2H), 1.48 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 155.9, 154.9, 154.7, 151.5, 149.7, 137.9, 130.0, 128.8, 127.2, 100.6, 96.4, 79.7, 43.8, 36.4, 29.4, 28.5, 14.8. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₃H₂₉N₄O₂⁺, 393.2285; found 393.2286.

tert-Butyl 4-(2-isopropyl-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8aha): The reaction was performed according to the general procedure employing 37.6 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6h**, 61.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5a** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a** with slight modification in reaction concentration (0.200 M, 1.50 mL of dioxane). Purification by silica gel column chromatography (10–40% Et₂O/hexanes) afforded **8aha** (81.7 mg, 65%) as a white solid. mp 100–102 °C. FTIR (neat) 2957, 1704, 1613, 1554, 1417, 1365, 1232, 1170, 1124, 766, 683, 439 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 8.06–7.96 (m, 2H), 7.51–7.41 (m, 3H), 6.97 (s, 1H), 6.51 (s, 1H), 4.43–4.17 (m, 2H), 3.75 (tt, *J* = 12.1, 3.4 Hz, 1H), 3.17 (hept, *J* = 6.9 Hz, 1H), 3.02–2.92 (m, 2H), 2.27–2.16 (m, 2H), 1.81–1.64 (m, 2H), 1.48 (s, 9H), 1.37 (d, *J* = 7.0 Hz, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 165.2, 155.7, 154.7, 151.6, 149.4, 137.9, 129.9, 128.8, 127.2, 100.6, 93.3, 79.7, 43.9, 36.4, 29.2, 28.8, 28.5, 22.9. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₅H₃₃N₄O₂⁺, 421.2598; found 421.2596.

tert-Butyl 4-(2-cyclopropyl-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8aia): The reaction was performed according to the general procedure employing 37.0 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6i**, 61.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5a** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a** with slight modification in reaction concentration (0.200 M, 1.50 mL of dioxane). Purification by silica gel column chromatography (2–10% EtOAc/CH₂Cl₂) afforded **8aia** (70.4 mg, 56%) as a white solid. mp 108–110 °C. FTIR (neat) 1964, 1611, 1557, 1419, 1366, 1272, 1226, 1159, 1120, 981, 769, 685, 661 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 8.07–7.95 (m, 2H), 7.54–7.37 (m, 3H), 6.95 (s, 1H), 6.30 (s, 1H), 4.46–4.16 (m, 2H), 3.74 (tt, *J* = 12.1, 3.2 Hz, 1H), 2.96 (m, 2H), 2.27–2.08 (m, 3H), 1.77–1.64 (m, 2H), 1.48 (s, 9H), 1.11–1.01 (m, 2H), 0.95–0.85 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 161.5, 155.8, 154.7, 151.3, 149.6, 137.9, 130.0, 128.8, 127.1, 100.5, 92.4, 79.7, 43.8, 36.4, 29.3, 28.5, 10.2, 9.4. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₅H₃₁N₄O₂⁺, 419.2442; found 419.2445.

tert-Butyl 4-(2,5-diphenylpyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8aja): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6j**, 61.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5a** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a** with slight modification in reaction concentration (0.200 M, 1.50 mL of dioxane). Purification by silica gel column chromatography (2–10% EtOAc/CH₂Cl₂) afforded **8aja** (70.6 mg, 52%) as an

off-white solid. mp 171–173 °C. FTIR (neat) 1662, 1612, 1464, 1420, 1236, 1165, 1134, 764, 744, 691 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 8.07 (d, *J* = 6.7 Hz, 2H), 8.03 (d, *J* = 6.9 Hz, 2H), 7.55–7.44 (m, 5H), 7.40 (t, *J* = 7.4 Hz, 1H), 7.06 (s, 1H), 7.01 (s, 1H), 4.51–4.23 (m, 2H), 3.86 (tt, *J* = 12.1, 3.4 Hz, 1H), 3.09–2.90 (m, 2H), 2.33–2.24 (m, 2H), 1.86–1.71 (m, 2H), 1.50 (s, 9H). ¹³C NMR (151 MHz, CDCl₃) δ 156.1, 155.9, 154.7, 151.8, 150.1, 137.7, 133.1, 130.2, 128.9, 128.7, 127.2, 126.6, 101.5, 93.8, 79.8, 44.3, 43.4, 36.7, 29.3, 28.5. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₈H₃₁N₄O₂⁺, 455.2442; found 455.2434.

tert-Butyl 4-(5-phenyl-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8aka): The reaction was performed according to the general procedure employing 45.6 mg (0.300 mmol) of aminopyrazole **6k**, 61.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5a** and 137 mg (0.450 mmol, 1.50 equiv) of ylide **7a**. Purification by silica gel column chromatography (100% CH₂Cl₂, then 10–25% EtOAc/hexanes) afforded **8aka** (102 mg, 76%) as an off-white solid. mp 164–167 °C. FTIR (neat) 1684, 1612, 1423, 1232, 1161, 1128, 1103, 955, 774, 692 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 8.10–8.05 (m, 2H), 7.56–7.50 (m, 3H), 7.23 (s, 1H), 6.98 (s, 1H), 4.52–4.19 (m, 2H), 3.80 (tt, *J* = 12.1, 3.4 Hz, 1H), 3.10–2.91 (m, 2H), 2.28–2.19 (m, 2H), 1.83–1.68 (m, 2H), 1.50 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 157.8, 154.8, 152.9, 149.2, 146.8 (q, *J* = 38.2 Hz), 137.1, 131.0, 129.2, 127.5, 121.4 (q, *J* = 269.7 Hz), 103.8, 95.9, 80.0, 43.8, 36.6, 29.4, 28.6. ¹⁹F NMR (376 MHz, CDCl₃) δ -62.4. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₃H₂₆F₃N₄O₂⁺, 447.2002; found 447.1996.

General Procedure for Two-Step, One-Pot Annulations with Aminopyrazoles, Aldehydes and Formyl Sulfoxonium Ylide **7i** (0.3 mmol scale).

To a flame-dried 2–5 mL Biotage microwave vial (#351521) charged with a stir bar on the benchtop were added aminopyrazole (0.300 mmol, 1.00 equiv), aldehyde (0.600 mmol, 2.00 equiv), PivOH (1.20 mmol, 4.00 equiv, 123 mg), 3 Å molecular sieves (approximately 300 mg) and dioxane (0.200 M, 1.50 mL). The vial was capped with a Teflon-lined cap, flushed with nitrogen for about 2 min, and then heated with a Biotage Initiator+ (#356007), which employs an external IR sensor and a closed reaction vessel. The resultant mixture was stirred in the microwave reactor for 30 min at 150 °C using the following settings (absorption level, low; vial type, 2–5 mL; prestirring, 0; initial power, 0; dynamic deflector optimization, ON; pressure: OFF; power, OFF; fixed hold time, ON; stir rate, 600). After cooling to rt, the cap was opened, and [Cp*Rh(MeCN)₃](SbF₆)₂ (10 mol %, 0.030 mmol, 25 mg), KOAc (0.30 mmol, 1.0 equiv, 29 mg) and formyl sulfoxonium ylide **7i** (0.330 mmol, 1.10 equiv, 39.7 mg) were added. The vial was capped with a Teflon-lined cap, flushed with nitrogen for about 2 min and then heated in the microwave reactor for 1 h at 150 °C using the above settings. After cooling to rt, the crude mixture was transferred to a separatory funnel with CH₂Cl₂ (50 mL). PivOH was removed by extracting with satd. NaHCO₃ (100 mL). The organic layer was separated, and the aqueous layer was extracted with CH₂Cl₂ (2 × 50 mL). The combined organic extracts were washed with satd. NaHSO₃ (10 % wt, 100 mL) to remove remaining aldehyde.¹⁶ The organic layer was dried (anhyd. Na₂SO₄) and concentrated under reduced pressure. The product was purified by silica gel column chromatography.

3,5-Diphenylpyrazolo[1,5-a]pyrimidine (8aai): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a** and 61.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5a**. Purification by silica gel column chromatography (2–5% EtOAc/ CH_2Cl_2) afforded **8aai** (63.5 mg, 78%) as a yellow solid. mp 135–137 $^\circ\text{C}$. FTIR (neat) 1612, 1559, 1521, 1493, 1413, 1267, 1192, 972, 815, 758, 682, 635, 549 cm^{-1} . ^1H NMR (400 MHz, CDCl_3) δ 8.66 (d, $J = 7.4$ Hz, 1H), 8.44 (s, 1H), 8.22–8.12 (m, 4H), 7.57–7.42 (m, 5H), 7.32–7.25 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.9, 144.7, 143.2, 137.0, 135.3, 132.2, 130.6, 128.9, 128.7, 127.3, 126.2, 126.2, 110.7, 105.3. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{14}\text{N}_3^+$, 272.1182; found 272.1183.

3-Phenyl-5-(4-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine (8bai): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a** and 82.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5b**. Purification by silica gel column chromatography (2–5% EtOAc/ CH_2Cl_2) afforded **8bai** (77.9 mg, 77%) as a yellow solid. mp 130–132 $^\circ\text{C}$. FTIR (neat) 1619, 1414, 1329, 1318, 1122, 1104, 1071, 1015, 810, 766, 752, 691 cm^{-1} . ^1H NMR (400 MHz, CDCl_3) δ 8.69 (d, $J = 7.3$ Hz, 1H), 8.46 (s, 1H), 8.24 (d, $J = 8.2$ Hz, 2H), 8.16–8.08 (m, 2H), 7.77 (d, $J = 8.2$ Hz, 2H), 7.47 (t, $J = 7.8$ Hz, 2H), 7.32–7.23 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 154.1, 144.5, 143.5, 140.2, 135.6, 132.1 (q, $J = 32.7$ Hz), 131.8, 128.8, 127.6, 126.5, 126.3, 125.9 (q, $J = 3.8$ Hz), 123.9 (q, $J = 272.3$ Hz), 111.3, 105.1. ^{19}F NMR (376 MHz, CDCl_3) δ –62.8. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{13}\text{F}_3\text{N}_3^+$, 340.1056; found 340.1053.

5-(4-Methoxyphenyl)-3-phenylpyrazolo[1,5-a]pyrimidine (8cai): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a** and 73.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5c**. Purification by silica gel column chromatography (2–5% EtOAc/ CH_2Cl_2) afforded **8cai** (66.4 mg, 73%) as a yellow solid. mp 136–138 $^\circ\text{C}$. FTIR (neat) 1604, 1563, 1412, 1251, 1180, 1023, 845, 789, 767, 694, 547 cm^{-1} . ^1H NMR (400 MHz, CDCl_3) δ 8.60 (d, $J = 7.4$ Hz, 1H), 8.41 (s, 1H), 8.21–8.06 (m, 4H), 7.46 (t, $J = 7.8$ Hz, 2H), 7.31–7.17 (m, 2H), 7.02 (d, $J = 8.9$ Hz, 2H), 3.87 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 161.7, 155.5, 144.7, 143.0, 135.1, 132.3, 129.5, 128.9, 128.7, 126.1, 126.0, 114.3, 110.2, 104.8, 55.4. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{16}\text{N}_3\text{O}^+$, 302.1288; found 302.1300.

5-(3-Bromophenyl)-3-phenylpyrazolo[1,5-a]pyrimidine (8dai): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a** and 70.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5d**. Purification by silica gel column chromatography (2–5% EtOAc/ CH_2Cl_2) afforded **8dai** (91.4 mg, 87%) as a yellow solid. mp 115–117 $^\circ\text{C}$. FTIR (neat) 1610, 1558, 1492, 1406, 1260, 1194, 780, 762, 686, 548, 535 cm^{-1} . ^1H NMR (400 MHz, CDCl_3) δ 8.68 (d, $J = 7.4$ Hz, 1H), 8.45 (s, 1H), 8.28 (t, $J = 1.8$ Hz, 1H), 8.17–8.10 (m, 2H), 8.08 (dt, $J = 7.6, 1.2$ Hz, 1H), 7.61 (ddd, $J = 8.0, 2.0, 1.0$ Hz, 1H), 7.48 (t, $J = 7.8$ Hz, 2H), 7.39 (t, $J = 7.9$ Hz, 1H), 7.32–7.21 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 154.2, 144.5, 143.4, 139.0, 135.5, 133.4, 131.9, 130.4, 130.3, 128.8, 126.4, 126.3, 125.9, 123.2, 111.1, 105.1. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{13}\text{BrN}_3^+$, 350.0287; found 350.0294.

5-(6-Chloropyridin-3-yl)-3-phenylpyrazolo[1,5-a]pyrimidine (8kai): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a** and 84.9 mg (0.600 mmol, 2.00 equiv) of aldehyde **5k**. Purification by silica gel column chromatography (2–10% EtOAc/CH₂Cl₂) afforded **8kai** (73.9 mg, 80%) as a yellow solid. mp > 240 °C. FTIR (neat) 1612, 1560, 1413, 1314, 1129, 1104, 1022, 971, 817, 768, 500, 472 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 9.10 (d, *J* = 2.5 Hz, 1H), 8.71 (d, *J* = 7.4 Hz, 1H), 8.46 (s, 1H), 8.43 (dd, *J* = 8.4, 2.6 Hz, 1H), 8.16–8.02 (m, 2H), 7.52–7.40 (m, 3H), 7.31–7.25 (m, 1H), 7.23 (d, *J* = 7.4 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 153.3, 152.0, 148.4, 144.4, 143.6, 137.2, 135.9, 131.62, 131.58, 128.8, 126.6, 126.2, 124.6, 111.3, 104.5. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₁₇H₁₂ClN₄⁺, 307.0745; found 307.0748.

5-(1-Methyl-1H-pyrazol-4-yl)-3-phenylpyrazolo[1,5-a]pyrimidine (8nai): The reaction was performed according to the general procedure employing 47.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6a** and 66.1 mg (0.600 mmol, 2.00 equiv) of aldehyde **5n**. Purification by silica gel column chromatography (10–35% EtOAc/CH₂Cl₂) afforded **8nai** (54.3 mg, 66%) as a yellow solid. mp 172–174 °C. FTIR (neat) 1616, 1583, 1551, 1514, 1236, 1187, 992, 887, 863, 808, 768, 690, 555, 516 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 8.54 (d, *J* = 7.3 Hz, 1H), 8.37 (s, 1H), 8.12–8.06 (m, 2H), 8.04 (d, *J* = 1.9 Hz, 2H), 7.44 (t, *J* = 7.8 Hz, 2H), 7.30–7.20 (m, 1H), 6.93 (d, *J* = 7.3 Hz, 1H), 3.98 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 151.0, 144.7, 143.0, 138.5, 135.1, 132.3, 130.1, 128.7, 126.1, 126.0, 122.2, 109.6, 105.4, 39.4. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₁₆H₁₄N₅⁺, 276.1244; found 276.1247.

2-Methyl-3,5-diphenylpyrazolo[1,5-a]pyrimidine (8aci): The reaction was performed according to the general procedure employing 52.0 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6c** and 61.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5a**. Purification by silica gel column chromatography (5–25% EtOAc/hexanes) afforded **8aci** (70.2 mg, 82%) as a yellow solid. mp 138–140 °C. FTIR (neat) 1609, 1559, 1493, 1422, 816, 767, 700, 689, 594 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 8.59 (d, *J* = 7.3 Hz, 1H), 8.16–8.06 (m, 2H), 7.88–7.81 (m, 2H), 7.54–7.41 (m, 5H), 7.35–7.28 (m, 1H), 7.23 (d, *J* = 7.4 Hz, 1H), 2.67 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 155.7, 153.0, 145.9, 137.1, 134.4, 132.5, 130.3, 128.8, 128.7, 128.4, 127.2, 126.1, 109.3, 104.7, 14.5. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₁₉H₁₆N₃⁺, 286.1339; found 286.1343.

2-Ethyl-3-methyl-5-phenylpyrazolo[1,5-a]pyrimidine (8adi): The reaction was performed according to the general procedure employing 37.6 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6d** and 61.0 μL (0.600 mmol, 2.00 equiv) of aldehyde **5a**. Purification by silica gel column chromatography (5–20% EtOAc/hexanes) afforded **8adi** (51.1 mg, 72%) as a yellow solid. mp 77–79 °C. FTIR (neat) 1611, 1515, 1494, 1260, 1086, 1020, 795, 764, 742, 682, 645, 534 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 8.52 (d, *J* = 7.3 Hz, 1H), 8.14–8.03 (m, 2H), 7.54–7.40 (m, 3H), 7.09 (d, *J* = 7.3 Hz, 1H), 2.84 (q, *J* = 7.6 Hz, 2H), 2.34 (s, 3H), 1.34 (t, *J* = 7.6 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 159.2, 154.3, 146.6, 137.6, 134.3, 130.0, 128.8, 127.0, 103.8, 103.0, 20.8, 13.3, 6.8. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₁₅H₁₆N₃⁺, 238.1339; found 238.1338.

5-Phenylpyrazolo[1,5-a]pyrimidine (8aei): The reaction was performed according to the general procedure employing 25.0 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6e** and 61.0 μ L (0.600 mmol, 2.00 equiv) of aldehyde **5a** with slight modification in reaction concentration (0.100 M, 3.00 mL of dioxane). Purification by silica gel column chromatography (5–20% EtOAc/hexanes) afforded **8aei** (17.5 mg, 30%) as a yellow solid. ^1H and ^{13}C NMR spectra matched with previously reported literature.¹⁷ ^1H NMR (600 MHz, CDCl_3) δ 8.69 (d, J = 7.3 Hz, 1H), 8.12 (d, J = 2.3 Hz, 1H), 8.09–8.05 (m, 2H), 7.55–7.45 (m, 3H), 7.26 (d, J = 7.4 Hz, 1H), 6.71 (d, J = 2.2 Hz, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.2, 148.5, 145.6, 137.1, 135.1, 130.5, 129.0, 127.2, 105.5, 97.0.

2-(tert-Butyl)-5-phenylpyrazolo[1,5-a]pyrimidine (8afi): The reaction was performed according to the general procedure employing 41.8 mg (0.300 mmol, 1.00 equiv) of aminopyrazole **6f** and 61.0 μ L (0.600 mmol, 2.00 equiv) of aldehyde **5a** with slight modification in reaction concentration (0.100 M, 3.00 mL of dioxane). Purification by silica gel column chromatography (10–30% Et_2O /hexanes) afforded **8afi** (45.7 mg, 61%) as a tan solid. mp 88–90 $^\circ\text{C}$. FTIR (neat) 1609, 1544, 1415, 1358, 1242, 793, 765, 739, 689 cm^{-1} . ^1H NMR (400 MHz, CDCl_3) δ 8.61 (d, J = 7.3 Hz, 1H), 8.09–7.97 (m, 2H), 7.54–7.42 (m, 3H), 7.15 (d, J = 7.3 Hz, 1H), 6.54 (s, 1H), 1.42 (s, 9H). ^{13}C NMR (101 MHz, CDCl_3) δ 168.8, 155.7, 148.9, 137.4, 134.7, 130.2, 128.9, 127.1, 104.5, 93.2, 32.8, 30.4. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{18}\text{N}_3^+$, 252.1495; found 252.1485.

General Procedure for Two-Step, One-Pot Annulations Using Ethyl Glyoxylate **5p** as the Aldehyde (0.3 mmol scale).

To a flame-dried 2–5 mL Biotage microwave vial (#351521) charged with a stir bar on the benchtop were added aminopyrazole **6a** (0.300 mmol, 1.00 equiv, 47.8 mg), PivOH (1.20 mmol, 4.00 equiv, 123 mg) and 3 \AA molecular sieves (approximately 300 mg). The vial was capped with a Teflon-lined cap and flushed with nitrogen for about 2 min. Under positive nitrogen pressure, the solution of ethyl glyoxylate **5p** (65.4 μ L of a 50% v/v in toluene, 0.330 mmol, 1.10 equiv) in dioxane (0.100 M, 3.00 mL) was quickly added. The reaction mixture was then heated with a Biotage Initiator+ (#356007), which employs an external IR sensor and a closed reaction vessel. The resultant mixture was stirred in the microwave reactor for 30 min at 150 $^\circ\text{C}$ using the following settings (absorption level, low; vial type, 2–5 mL; prestirring, 0; initial power, 0; dynamic deflector optimization, ON; pressure: OFF; power, OFF; fixed hold time, ON; stir rate, 600). After cooling to rt, the cap was opened, and $[\text{Cp}^*\text{Rh}(\text{MeCN})_3](\text{SbF}_6)_2$ (10 mol %, 0.030 mmol, 25 mg), KOAc (0.30 mmol, 1.0 equiv, 29 mg) and sulfoxonium ylide **7a** (0.450 mmol, 1.50 equiv, 137 mg) or formyl sulfoxonium ylide **7i** (0.330 mmol, 1.10 equiv, 39.7 mg) were added. The vial was capped with a Teflon-lined cap, flushed with nitrogen for about 2 min and then heated in the microwave reactor for 1 h at 150 $^\circ\text{C}$ using the above settings. After cooling to rt, the crude mixture was transferred to a separatory funnel with CH_2Cl_2 (50 mL). PivOH was removed by extracting with satd. NaHCO_3 (100 mL). The organic layer was separated, and the aqueous layer was extracted with CH_2Cl_2 (2 \times 50 mL). The combined organic extracts were dried (anhyd. Na_2SO_4) and concentrated under reduced pressure. The product was purified by silica gel column chromatography.

Ethyl 7-(1-(tert-butoxycarbonyl)piperidin-4-yl)-3-phenylpyrazolo[1,5-a]pyrimidine-5-carboxylate (8paa): The reaction was performed according to the general procedure employing 137 mg (0.450 mmol, 1.50 equiv) of sulfoxonium ylide **7a**. Purification by silica gel column chromatography (10–30% EtOAc/hexanes) afforded **8paa** (111 mg, 82%) as a yellow solid. mp 140–142 °C. FTIR (neat) 1717, 1691, 1668, 1427, 1239, 1171, 866, 765, 728, 693 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 8.51 (s, 1H), 8.12–8.06 (m, 2H), 7.45 (t, *J* = 7.7 Hz, 2H), 7.39 (s, 1H), 7.31–7.25 (m, 1H), 4.49 (q, *J* = 7.1 Hz, 2H), 4.43–4.21 (m, 2H), 3.76 (tt, *J* = 12.1, 3.4 Hz, 1H), 3.06–2.88 (m, 2H), 2.23–2.15 (m, 2H), 1.80–1.66 (m, 2H), 1.48 (s, 9H), 1.46 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 164.2, 154.6, 152.8, 146.5, 144.2, 142.9, 131.4, 128.8, 126.8, 126.6, 113.2, 103.7, 79.8, 62.4, 43.9, 36.7, 29.0, 28.4, 14.2. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₅H₃₁N₄O₄⁺, 451.2340; found 451.2339.

Ethyl 3-phenylpyrazolo[1,5-a]pyrimidine-5-carboxylate (8pai): The reaction was performed according to the general procedure employing 39.7 mg (0.330 mmol, 1.10 equiv) of formyl sulfoxonium ylide **7i**. Purification by silica gel column chromatography (10–30% EtOAc/hexanes) afforded **8pai** (64.6 mg, 81%) as a yellow solid. mp 120–122 °C. FTIR (neat) 1724, 1297, 1138, 1015, 761, 685, 602, 556 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 8.74 (d, *J* = 7.3 Hz, 1H), 8.52 (s, 1H), 8.13–8.01 (m, 2H), 7.53 (d, *J* = 7.3 Hz, 1H), 7.45 (t, *J* = 7.8 Hz, 2H), 7.33–7.25 (m, 1H), 4.49 (q, *J* = 7.1 Hz, 2H), 1.46 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 163.7, 146.5, 143.8, 143.7, 135.5, 131.1, 128.9, 126.9, 126.5, 113.3, 107.5, 62.5, 14.2. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₁₅H₁₄N₃O₂⁺, 268.1081; found 268.1078.

General Procedure for Two-Step, One-Pot Annulations Using Trimethyl Orthoformate **5q** as the Aldehyde (0.3 mmol scale).

To a flame-dried 2–5 mL Biotage microwave vial (#351521) charged with a stir bar on the benchtop were added aminopyrazole **6a** (0.300 mmol, 1.00 equiv, 47.8 mg) and PivOH (1.20 mmol, 4.00 equiv, 123 mg). The vial was capped with a Teflon-lined cap and flushed with nitrogen for about 2 min. Under positive nitrogen pressure, the solution of trimethyl orthoformate **5q** (0.33 mL, 3.0 mmol, 10 equiv) in dioxane (0.100 M, 3.00 mL) was quickly added. The reaction mixture was then heated with a Biotage Initiator+ (#356007), which employs an external IR sensor and a closed reaction vessel. The resultant mixture was stirred in the microwave reactor for 30 min at 150 °C using the following settings (absorption level, low; vial type, 2–5 mL; prestirring, 0; initial power, 0; dynamic deflector optimization, ON; pressure: OFF; power, OFF; fixed hold time, ON; stir rate, 600). After cooling to rt, the cap was opened, and [Cp*Rh(MeCN)₃](SbF₆)₂ (10 mol %, 0.030 mmol, 25 mg), KOAc (0.30 mmol, 1.0 equiv, 29 mg) and sulfoxonium ylide **7a** (0.450 mmol, 1.50 equiv, 137 mg) or formyl sulfoxonium ylide **7i** (0.330 mmol, 1.10 equiv, 39.7 mg) were added. The vial was capped with a Teflon-lined cap, flushed with nitrogen for about 2 min and then heated in the microwave reactor for 1 h at 150 °C using the above settings. After cooling to rt, the crude mixture was transferred to a separatory funnel with CH₂Cl₂ (50 mL). PivOH was removed by extracting with satd. NaHCO₃ (100 mL). The organic layer was separated, and the aqueous layer was extracted with CH₂Cl₂ (2 × 50 mL). The combined organic extracts were

dried (anhyd. Na₂SO₄) and concentrated under reduced pressure. The product was purified by silica gel column chromatography.

tert-Butyl 4-(5-methoxy-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate (8qaa): The reaction was performed according to the general procedure employing 137 mg (0.450 mmol, 1.50 equiv) of sulfoxonium ylide **7a**. Purification by silica gel column chromatography (10–20% EtOAc/hexanes) afforded **8qaa** (95.4 mg, 78%) as a white solid. mp 135–137 °C. FTIR (neat) 1684, 1629, 1545, 1426, 1392, 1229, 1167, 1120, 945, 865, 762, 692 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 8.29 (s, 1H), 8.06–7.97 (m, 2H), 7.41 (t, *J* = 7.7 Hz, 2H), 7.24–7.16 (m, 1H), 6.17 (s, 1H), 4.41–4.17 (m, 2H), 4.06 (s, 3H), 3.62 (tt, *J* = 12.1, 3.4 Hz, 1H), 3.05–2.83 (m, 2H), 2.19–2.08 (m, 2H), 1.69–1.54 (m, 2H), 1.47 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 162.2, 154.7, 153.9, 143.7, 141.8, 132.5, 128.6, 125.6, 108.4, 95.9, 79.7, 53.9, 43.7, 36.4, 29.4, 28.4. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₃H₂₉N₄O₃⁺, 409.2234; found 409.2236.

5-Methoxy-3-phenylpyrazolo[1,5-a]pyrimidine (8qai): The reaction was performed according to the general procedure employing 39.7 mg (0.330 mmol, 1.10 equiv) of formyl sulfoxonium ylide **7i**. Purification by silica gel column chromatography (10–20% EtOAc/hexanes) afforded **8qai** (24.3 mg, 36%) as a yellow solid. mp 84–86 °C. FTIR (neat) 1633, 1535, 1434, 1405, 1285, 1184, 1019, 946, 793, 757, 686, 512 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 8.40 (d, *J* = 7.4 Hz, 1H), 8.30 (s, 1H), 8.06–7.97 (m, 2H), 7.42 (t, *J* = 7.6 Hz, 2H), 7.26–7.18 (m, 1H), 6.35 (d, *J* = 7.4 Hz, 1H), 4.08 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 161.8, 143.3, 142.8, 137.0, 132.3, 128.6, 125.7, 125.6, 108.3, 100.2, 54.1. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₁₃H₁₂N₃O⁺, 226.0975; found 226.0973.

Procedure for Three-Component Reaction of Aminopyrazole **6a**, Aldehyde **5n** and β-Keto Sulfoxonium Ylide **7a** (1 mmol scale).

To a flame-dried 2–5 mL Biotage microwave vial (#351521) charged with a stir bar on the benchtop were added aminopyrazole **6a** (1.00 mmol, 1.00 equiv, 159 mg), aldehyde **5n** (2.00 mmol, 2.00 equiv, 220 mg), [Cp*Rh(MeCN)₃](SbF₆)₂ (5 mol %, 0.0500 mmol, 41.7 mg), PivOH (4.00 mmol, 4.00 equiv, 409 mg), KOAc (1.00 mmol, 1.00 equiv, 98.1 mg), 3Å molecular sieves (approximately 1 g), sulfoxonium ylide **7a** (1.50 mmol, 1.50 equiv, 455 mg) and dioxane (0.400 M, 2.50 mL). The vial was capped with a Teflon-lined cap, flushed with nitrogen for about 5 min, and then heated with a Biotage Initiator+ (#356007), which employs an external IR sensor and a closed reaction vessel. The resultant mixture was stirred in the microwave reactor for 1 h at 150 °C using the following settings (absorption level, low; vial type, 2–5 mL; prestirring, 0; initial power, 0; dynamic deflector optimization, ON; pressure: OFF; power, OFF; fixed hold time, ON; stir rate, 600). After cooling to rt, the crude mixture was transferred to a separatory funnel with CH₂Cl₂ (150 mL). PivOH was removed by extraction with satd. NaHCO₃ (300 mL). The organic layer was separated, and the aqueous layer was extracted with CH₂Cl₂ (2 × 150 mL). The combined organic extracts were washed with satd. NaHSO₃ (10 % wt, 300 mL) to remove the remaining aldehyde.¹⁶ The organic layer was dried (anhyd. Na₂SO₄) and concentrated under reduced pressure. Purification by silica gel column chromatography (5–30% EtOAc/CH₂Cl₂) afforded **8naa**

(351 mg, 77%) as a light yellow solid. ^1H and ^{13}C NMR spectra matched with **8naa** obtained from small scale (0.3 mmol).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENT

This work was supported by the NIH (R35GM122473 to J.A.E).


REFERENCES

- (1). For representative approved drugs and clinical candidates of the pyrazolopyrimidine subclass, see: zaleplon, anagliptin, larotrectinib sulfate, indiplon, remeglurant, verucerfont, lorediplon, ropotrectinib, decoglurant, presatovir, ocinaplon, dinaciclib, TAK-43, IPI-549, OT-7100, AVN-322, AVN-211, MK-8776. The compound structure, bioactivity, list of literature, and access to ongoing clinical trials, applications, and usage can be obtained by searching the compound name in PubChem.
- (2). For representative approved drugs and clinical candidates within this heterocycle framework outside of the pyrazolopyrimidine subclass, see: zolpidem, alpidem, olprinone, zolimidine, miroprofen, necopidem, saripidem, minodronic acid, GSK812397, soraprazan, divaplon, faspilon. The compound structure, bioactivity, list of literature, and access to ongoing clinical trials, applications, and usage can be obtained by searching the compound name in PubChem.
- (3). Halskov KS; Witten MR; Hoang GL; Mercado BQ; Ellman JA Rhodium(III)-Catalyzed Imidoyl C–H Activation for Annulations to Azolopyrimidines. *Org. Lett* 2018, 20, 2464–2467. [PubMed: 29582661]
- (4). For reviews on the synthesis of nitrogen heterocycles by C–H functionalization, see; For select reviews, see: Satoh T; Miura M Oxidative Coupling of Aromatic Substrates with Alkynes and Alkenes under Rhodium Catalysis. *Chem. Eur. J* 2010, 16, 11212–11222. [PubMed: 20740508] Yamaguchi J; Yamaguchi AD; Itami K C–H Bond Functionalization: Emerging Synthetic Tools for Natural Products and Pharmaceuticals. *Angew. Chem. Int. Ed* 2012, 51, 8960–9009. Song G; Wang F; Li X C–C, C–O and C–N Bond Formation via Rhodium(III)-Catalyzed Oxidative C–H Activation. *Chem. Soc. Rev* 2012, 41, 3651–3678. [PubMed: 22377832] Guliás M; Mascareñas JL Metal-Catalyzed Annulations through Activation and Cleavage of C–H Bonds. *Angew. Chem. Int. Ed* 2016, 55, 11000–11019. Yoshino T; Matsunaga S (Pentamethylcyclopentadienyl)cobalt(III)-Catalyzed C–H Bond Functionalization: From Discovery to Unique Reactivity and Selectivity. *Adv. Synth. Catal* 2017, 359, 1245–1262. Hummel JR; Boerth JA; Ellman JA Transition-Metal-Catalyzed C–H Bond Addition to Carbonyls, Imines, and Related Polarized π Bonds. *Chem. Rev* 2017, 117, 9163–9227. [PubMed: 27936637]
- (5). Hoang GL; Halskov KS; Ellman JA Synthesis of Azolo[1,3,5]triazines via Rhodium(III)-Catalyzed Annulation of *N*-Azolo Imines and Dioxazolones. *J. Org. Chem* 2018, 83, 9522–9529. [PubMed: 29947517]
- (6). Park Y; Kim Y; Chang S Transition Metal-Catalyzed C–H Amination: Scope, Mechanism, and Applications. *Chem. Rev* 2017, 117, 9247–9301; and references cited therein. [PubMed: 28051855]
- (7). Shaanban S; Abdel-Wahab BF Groebke–Blackburn–Bienaymé Multicomponent Reaction: Emerging Chemistry for Drug Discovery. *Mol. Divers* 2016, 20, 233–254; and references cited therein. [PubMed: 26016721]
- (8). For leading references on sulfoxonium ylides as carbene precursors, see: Baldwin JE; Adlington RM, Godfrey CRA; Gollins DW; Vaughan JG *J. A Novel Entry to Carbenoid Species via β -Ketosulfoxonium Ylides*. *Chem. Soc., Chem. Commun* 1993, 1434–1435. Mangion IK; Nwamba IK; Shevlin M; Huffman MA Iridium-Catalyzed X–H Insertions of Sulfoxonium Ylides. *Org.*


Lett 2009, 11, 3566–3569. [PubMed: 19618903] Burtoloso ACB; Dias RMP; Leonarczyk IA Sulfoxonium and Sulfonium Ylides as Diazocarbonyl Equivalents in Metal-Catalyzed Insertion Reactions. *Eur. J. Org. Chem* 2013, 5005–5016. Neuhaus JD; Oost R; Merad J; Maulide N Sulfur-Based Ylides in Transition-Metal-Catalysed Processes. *Top. Curr. Chem* 2018, 317, 1–47.

- (9). For leading references on the application of sulfoxonium ylides in Rh(III)-catalyzed C–H functionalization, see:
- (a). Xu Y; Zhou X; Zheng G; Li X Sulfoxonium Ylides as a Carbene Precursor in Rh(III)-Catalyzed C–H Acylmethylation of Arenes. *Org. Lett* 2017, 19, 5256–5259. [PubMed: 28901774]
- (b) Barday M; Janot C; Halcovitch NR; Muir J; Aïssa C Cross-Coupling of α -Carbonyl Sulfoxonium Ylides with C–H Bonds. *Angew. Chem. Int. Ed* 2017, 56, 13117–13121.
- (c) Wu X; Xiong H; Sun S; Cheng J Rhodium-Catalyzed Relay Carbenoid Functionalization of Aromatic C–H Bonds toward Fused Heteroarenes. *Org. Lett* 2018, 20, 1396–1399. [PubMed: 29468881]
- (d) Zheng G; Tian M; Xu Y; Chen X; Li X Rhodium(III)-Catalyzed Annulative Coupling Between Arenes and Sulfoxonium Ylides via C–H Activation. *Org. Chem. Front* 2018, 5, 998–1002.
- (e) Xu Y; Zheng G; Yang X; Li X Rhodium(III)-Catalyzed Chemodivergent Annulations Between *N*-Methoxybenzamides and Sulfoxonium Ylides via C–H Activation. *Chem. Commun* 2018, 54, 670–673.
- (f) Hoang GL; Ellman JA Rhodium(III)-Catalyzed C–H Functionalization of C-alkenyl Azoles with Sulfoxonium Ylides for the Synthesis of Bridgehead *N*-fused [5,6]-Bicyclic Heterocycles. *Tetrahedron* 2018, 74, 3318–3324. [PubMed: 29988985]
- (g) Oh H; Han S; Pandey AK; Han SH; Mishra NK; Kim S; Chun R; Kim HS; Park J; Kim IS Synthesis of (2*H*)-Indazoles through Rh(III)-Catalyzed Annulation Reaction of Azobenzenes with Sulfoxonium Ylides. *J. Org. Chem* 2018, 83, 4070–4077. [PubMed: 29547287]
- (10). Manach CL; Paquet T; Brunschwig C; Njoroge M; Han Z; Cabrera DG; Bashyam S; Dhinakaran R; Taylor D; Reader J; Botha M; Churchyard A; Lauterbach S; Coetzer TL; Birkholtz L-M; Meister S; Winzeler EA; Waterson D; Witty MJ; Wittlin S; Jiménez-Díaz M-B; Martínez MS; Ferrer S; Angulo-Barturen I; Street LJ; Chibale K A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure–Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines. *J. Med. Chem* 2015, 58, 8713–8722. [PubMed: 26502160]
- (11). The compound structure, bioactivity, list of literature, and access to ongoing clinical trials, applications, and usage can be obtained by searching the compound name in PubChem.
- (12). Maquestiau A; Taghret H; Vanden Eynde J-J Preparation and characterization of pyrazolo[1,5-*a*]pyrimidines. *Bull. Soc. Chim. Belg* 1992, 101, 131–136.
- (13). Kelada M; Walsh JMD; Devine RW; McArdle P; Stephens JC Synthesis of Pyrazolopyrimidinones using a “One-pot” Approach under Microwave Irradiation. *Beilstein J. Org. Chem* 2018, 14, 1222–1228. [PubMed: 29977390]
- (14). Park Y; Park KT; Kim JG; Chang S Mechanistic Studies on the Rh(III)-Mediated Amido Transfer Process Leading to Robust C–H Amination with a New Type of Amidating Reagent. *J. Am. Chem. Soc* 2015, 137, 4534–4542. [PubMed: 25789561]
- (15). Kondo K; Tunemoto D Nuclear Magnetic Resonance Evidence for Restricted Rotation in Stable Oxosulphonium Ylides. *Chem. Commun* 1970, 1361–1362.
- (16). Boucher MM; Furigay MH; Quach PK; Brindle CS Liquid–Liquid Extraction Protocol for the Removal of Aldehydes and Highly Reactive Ketones from Mixtures. *Org. Process Res. Dev* 2017, 21, 1394–1403.
- (17). Jismy B; Guillaumet G; Allouchi H; Akssira M; Abarbri. M. Concise and Efficient Access to 5,7-Disubstituted Pyrazolo[1,5-*a*]pyrimidines by Pd-Catalyzed Sequential Arylation, Alkynylation and SN_{Ar} Reaction. *Eur. J. Org. Chem* 2017, 6168–6178.


A. Two-component Rh(III)-catalyzed imidoyl C–H activation for the synthesis of bridgehead *N*-fused [5,6]-bicyclic heterocycles



B. GBBR three-component reactions for the synthesis of bridgehead *N*-fused [5,6]-bicyclic heterocycles





C. This work: Three-component Rh(III)-catalyzed imidoyl C–H activation for the synthesis of pyrazolo[1,5-*a*]pyrimidines





Scheme 1.


Fused [5,6]-Bicyclic Bridgehead Nitrogen Heterocycle Synthesis


**Scheme 2.**Aldehyde Scope for Three-component Synthesis of Pyrazolopyrimidines **8**^a^a Standard conditions with **5** (0.60 mmol), **6a** (0.30 mmol), and **7a** (0.45 mmol). ^b 0.2 M.

**Scheme 3.**Sulfoxonium Ylide Scope for Three-Component Synthesis of Pyrazolopyrimidines **8**^a^a Standard conditions with **5a** (0.60 mmol), **6a** (0.30 mmol), and **7** (0.45 mmol)


**Scheme 4.**Aminopyrazole Scope for Three-Component Synthesis of Pyrazolopyrimidines **8**^a^a Standard conditions with **5a** (0.60 mmol), **6** (0.30 mmol), and **7a** (0.45 mmol). ^b 0.2 M

**Scheme 6.**Ethyl Glyoxylate as the Aldehyde^a^a **5p** (0.60 mmol), **6a** (0.30 mmol), **7** (0.45 mmol). ^b **7i** (1.1 equiv).

**Scheme 7.**Methoxy Group Introduction^a^a **5q** (3.0 mmol), **6a** (0.30 mmol), **7** (0.45 mmol). ^b **7i** (1.1 equiv).




Scheme 8.
Benchtop Reaction Set Up at 1 mmol Scale



Scheme 9.
Proposed Mechanism for Annulation

Table 1.

Reaction Parameters for Annulation to Pyrazolopyrimidine 8^a

entry	Variation	Yield % ^b
1	None	75
2	[Cp*RhCl ₂] ₂ (5%)	61
3	no Rh	0
4	NaOAc instead of KOAc	60
5	no KOAc	39
6	no PivOH	27
7	160 °C	73
8	chlorobenzene as solvent	57
9	ylide 7a (1.1 equiv)	67
10	[Cp*IrCl ₂] ₂ (5%) and AgSbF ₆ (20%)	28
11	[Cp*Co(MeCN) ₃](SbF ₆) ₂ (10%)	21
12	0.1 M	62
13	0.4 M	85 (82)^c
14	0.4 M, no sieves	75
15	0.4 M, [Cp*Rh(MeCN) ₃](SbF ₆) ₂ (5%)	77
16	0.4 M, [Cp*Rh(MeCN) ₃](SbF ₆) ₂ (2.5%)	38
17	0.4 M, conventional heating, 100 °C, 16 h	82

^aConditions: 5a (0.20 mmol), 6a (0.10 mmol), 7a (0.15 mmol)^bYield determined by ¹H-NMR relative to 1,3,5-trimethoxybenzene as external standard.^cIsolated yield of a 0.30 mmol scale (see Scheme 2).